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2 Abbreviations 
 
2-HG  2-Hydroxyglutarate 
α-KG α-Ketoglutarate 
Ala Alanine 
AML Acute myeloid leukemia 
APCI Atmospheric pressure chemical ionization 
Arg Arginine 
Asn Asparagine 
Asp Aspartate 
CE Capillary electrophoresis 
D-/L-2-HGA D-/L-2-Hydroxyglutaric aciduria 
D2HGDH; D2HDH D-2-Hydroxyglutarate dehydrogenase 
Da Dalton 
EI Electron ionization 
EIC Extracted ion chromatogram 
ESI Electrospray ionization 
FCS Fetal calf serum 
GC Gas chromatography 
Glc Glucose 
Gln Glutamine 
His Histidine 
IDH1/2, IDH1/2 Isocitrate dehydrogenase 1/2 
IS internal standard 
LC  Liquid chromatography 
LOD Limit of detection 
(L/U-)LOQ  (Lower/ upper) limit of quantification 
m/z Mass-to-charge ratio 
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MCT1/4; MCT1/4 Monocarboxylate transporter 1/4 
MID  Mass isotopomer distribution vector 
MeOH Methanol 
MeOx Methoximation 
mutIDH1/2 Mutated IDH1/2 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
NADP+/NADPH  Nicotinamide adenine dinucleotide phosphate 
(oxidized and reduced form) 
(1H-)NMR(-spectroscopy)  (Proton-)nuclear magnetic resonance              
(-spectroscopy) 
PBS Phosphate buffered saline 
 PC  Pyruvate carboxylase 
PFPP  Pentafluorophenyl propyl 
PPP Pentose phoshphate pathway 
Pro Proline 
QqQ Triple quadupole 
Ser Serine 
TCA Tricarboxylic acid cycle 
TIC Total ion current 
TOF Time-of-flight 
TMS Trimethylsilyl-moiety 
WT Wild type 
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3 Objectives 
3.1 Elucidate the mechanism of 2-HG-lactone formation 
This thesis was conducted within the framework of the KFO 262 “Tumor metabolism 
meets Immunology”, with special focus on the oncometabolite D-2-hydroxyglutarate 
(D-2-HG), which is produced by mutated isocitrate dehydrogenase IDH1/2 resulting in 
significantly increased concentrations of this metabolite.  
At the Institute of Functional Genomics preliminary work was performed to measure 
2-HG in different biological matrices. IDH1/2 mutations are frequently identified in 
gliomas and in AML (acute myeloid leukemia), accompanied by increased D-2-HG 
levels in tissue and serum, respectively. Interestingly, in serum from AML patients not 
only D-2-HG was detected, but also a closely related metabolite, which had not been 
described so far. The novel metabolite is the intramolecular ester of D-2-HG and 
therefore named D-2-HG-lactone (IUPAC: R-5-oxotetrahydrofuran-2-carboxylic acid) 
(Figure 1).  
 
Figure 1. Molecular structure of (R)-2-hydroxyglutarate and its lactone, 
(R)-5-oxotetrahydrofuran-2-carboxylic acid. 
Initially, 2-HG-lactone was detected by chiral GC-MS as a product of the derivatization 
of 2-HG with methyl chloroformate (MCF)1. The presence of multiple 2-HG-derivatives 
has already been described by others, e.g., by Duran et al. (1980) upon esterification 
of 2-HG with S-2-butanol and acylation with acetic anhydride2. However, while the ratio 
of the two derivatization products remained stable in the case of standard samples, it 
varied in AML serum samples (Figure 2).  This led to the hypothesis that the lactone 
was an endogenous metabolite. This was confirmed by LC-MS/MS and NMR analysis 
of an underivatized serum extract. 
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Figure 2. Chiral GC-MS analysis of a racemic D/L-2-HG standard (upper panel) and a serum 
sample of an AML patient carrying an IDH1/2 mutation (lower panel). For the standard sample, 
the area ratio of each enantiomer dervative of 2-HG-lactone (shown in black) to 2-HG (shown 
in red) was constant (4:1) across several measurements. In green and purple the respective 
stable isotope labeled internal standard is shown. For the exemplary AML serum sample, the 
ratio of D-2-HG-lactone/D-2-HG(-derivatives) was found to be increased (13.7:1) for the 
unlabeled, endogenous analyte. Besides, both L-forms are hardly detectable. (Capillary 
column was a Rt-gDEXsa, connected to an APCI-TOF-MS. Figure is based on data generated 
by C. Wachsmuth.) 
 
However, the lactone form is not observed in all tumor entities analyzed, raising the 
question about the origin of 2-HG-lactone. In general, ester formation is favored under 
acidic conditions, but a pH of ~5-6 seems insufficient to cause the detected 
2-HG-lactone concentrations. This thesis aims at finding the conditions and 
prerequisites for lactonization of 2-HG. For instance, it is investigated whether 
2-HG-lactone is a product of a so far unknown enzyme (activity). This includes the 
analysis of cell culture samples and several biological specimens by LC-MS/MS. 
Therefore, a HPLC system coupled to a triple-quadrupole mass spectrometer in MRM 
(multiple reaction monitoring) mode is used for quantification of 2-HG&-lactone. 
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Cell culture experiments are performed using several cell lines. There are cells with 
WT-IDH and cell with mutation of IDH, e.g. HT1080 and a panel of HCT116 cells 
(consisting of cells with mutations in IDH1 or IDH2, respectively, and the WT-IDH 
parental cell line).  
 
3.2 Investigate the metabolic fate of 2-HG and 2-HG-lactone 
It is further hypothesized that D-2-HG is metabolized by its dehydrogenase D2HDH 
and that this enzyme is upregulated in response to accumulation of the substrate. 
Therefore, enzyme activity in cell homogenates is determined in an enzyme assay to 
investigate potential regulation of enzyme kinetics. This LC-MS/MS-based assay has 
to be established to measure the decline of 2-HG. Regulation on the protein expression 
level is analyzed by Western Blot. 
Moreover, as a valuable technique for investigating the metabolic fate of 2-HG and its 
lactone in cell culture models, metabolic tracing is performed. Typical stable isotope 
labeled substrates ([U-13C]glutamine, [U-13C]glucose) are added to cell culture medium 
with subsequent tracing of the label into metabolic products. For analysis of those cell 
extracts, new derivatization strategies need to be found as established methods are 
unsuitable. Finally, this experiment provides data on metabolic effects of IDH1/2 
mutation. 
 
3.3 Analytical objectives 
For some of the aforementioned investigations, it is possible to use the already 
established LC-ESI-MS/MS method for quantification of 2-HG and 2-HG-lactone, but 
a thorough method validation has to be performed. However, this method is not 
applicable to enantioselective investigations. A method for chiral analysis of 2-HG is 
available, but cannot be extended to the analysis of 2-HG-lactone. Moreover, for 
analysis of labeling patterns, the LC-MS/MS method has to be extended by the 
respective transitions for 2-HG and 2-HG-lactone. In order to gain more information on 
cellular metabolism in the context of IDH1/2 mutation and elevated 2-HG levels, a more 
widespread method for tracer analysis is established. A GC-APCI-TOF-MS method 
gives valuable results. But here, like for other (GC-)MS-strategies involving 
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derivatization, work is hampered by the fact that 2-HG and 2-HG-lactone are closely 
related and are easily transformed into each other by harsh derivatization conditions. 
Consequently, various derivatization protocols are tested, especially for the attempt to 
perform chiral analysis.  
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4 Background 
4.1 IDH1/2 mutation and 2-hydroxyglutarate 
Cellular metabolism in cancer is known to be altered to meet the increased energy 
demand and biomolecule turnover. In this context, several mutations were identified 
facilitating cellular transformation, which included mutation of isocitrate 
dehydrogenase3. This enzyme has three isoforms in eukaryotic cells, cytosolic IDH1 
and mitochondrial IDH2/3, which all catalyze oxidative decarboxylation of isocitrate to 
α-ketoglutarate using redox equivalents as co-substrates4. To date, several non-
synonymous mutations have been found in the NADP+-dependent IDH1/2 that seem 
to be mutually exclusive5. IDH1/2 mutations have been found initially in colorectal 
cancer6, and are frequently identified in tumors of the central nervous system, like 
glioblastoma, and in patients with acute myeloid leukemia (AML)5,7. The most frequent 
mutation type in glial tumors is IDH1-R132H, which is found in 91.5% of patients with 
IDH1 mutation8. Other substitutions include R132C, R132G, R132S, and R132L. 
Mutations in IDH2 in gliomas are rare (<3%) and in most cases of the R172K type9, 
with R172 being the analogous residue to R132 in IDH1. In AML patients, the IDH2 
mutations R140Q and R172K are typically observed and these two mutations occur at 
a frequency of 15.4%, which is twice as much as mutIDH1 in AML10. Interestingly, all 
of the mutated residues are located in the active site of IDH1/2 and contribute to 
substrate binding via hydrogen bonds11. Accordingly, the mutations result in a neo-
enzymatic activity, i.e., the production of D-2-HG from α-ketoglutarate and its 
subsequent accumulation11. This corresponds to the almost reverse reaction 
compared to the WT-IDH1/2, only lacking the carboxylation step.  
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Figure 3. Scheme depicting the formation of D-2-HG in cell metabolism under both, 
physiological conditions and due to somatic mutations in IDH1/2 in cancer. 
Some authors described that IDH2 mutations result in higher concentrations of 2-HG 
compared to IDH1 mutations12-14. This seems to be due to the dependency of the latter 
isoform on metabolic flux through a WT-IDH1 to supply α-KG13. Therefore, IDH1 
mutations are generally heterozygous, with only one allele being mutated, whereas for 
IDH2 rare cases of biallelic mutations have been reported15 . MutIDH1/2 generate 
exclusively the D-enantiomer of 2-HG. The concentrations detected, for instance, in 
gliomas typically range from 5 to 35 mM, i.e., they are 10-100-fold higher compared to 
control samples without IDH1/2 mutations16. In healthy cells, 2-HG is produced only in 
low amounts (intracellular levels <0.1 mM)17 as side products of enzymes like HOT 
(hydroxyl acid-oxoacid-transhydrogenase)18 and PHGDH (phosphoglycerate 
dehydrogenase)19 (Figure 3). Enantiospecific dehydrogenases, named 
D-/L-2-hydroxyglutarate dehydrogenase (D-/L-2HGDH), assure the oxidation back to 
α-ketoglutarate. Deficiency of these enzymes due to germline mutations result in 
D-/L-2-hydroxyglutarate aciduria (D-/L-2-HGA) with similarly elevated 2-HG-levels in 
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urine, plasma and also in cerebrospinal fluid20,2,21. Clinical symptoms caused by 
pathological accumulation of 2-HG differ for the two enantiomers. L2HDH deficient 
patients suffer from encephalopathy and their risk of brain tumors like gliomas is 
increased22. Deficiency of D2HDH results in a neurometabolic disorder, which is 
associated with encephalopathy and cardiomyopathy, but not with cancer23. 
Additionally, there is D-2-HGA type II, which is caused by a germline mutation or 
mosaicism in IDH2, also resulting in elevated D-2-HG levels24,25. It is suggested that 
even functional D2HDH cannot cope with the extremely elevated 2-HG levels obtained 
when IDH1/2 is mutated due to a huge difference in the catalytic rate for 2-HG 
production and degradation11,26. 
D-2-HG is regarded as an oncometabolite, contributing to and in cooperation with other 
oncogenes even initiating oncogenesis27. The underlying mechanism(s) are currently 
still discussed. Its structural similarity to α-KG is known to exert inhibitory effects on 
α-KG-dependent enzymes and depicts possible ways of mediating transformation.  An 
example is the competitive inhibition of α-KG-dependent TET2 and histone 
demethylase KDM4C (also known as JMJD2C) resulting in DNA hypermethylation and 
an altered histone methylation pattern, respectively, which in turn block cell 
differentiation and change gene expression28,29. 
The L-enantiomer of 2-HG, in contrast, is increasingly produced under hypoxic 
conditions by promiscuous enzyme activity of lactate dehydrogenase (LDH) and 
malate dehydrogenase (MDH), which is further enhanced by acidic conditions30. The 
biological function in this context was found to be HIF1a-stabilization in adaptation to 
acidosis and hypoxia. These interactions again involve inhibition of α-KG-dependent-
dioxygenases, which was found to be stronger by L-2-HG than D-2-HG28,31,32. Thus, 
for 2-HG there are shared, as well as enantiospecific effects. 
Interestingly, mutations in other TCA enzymes, like fumarate hydratase (FH) and 
succinate dehydrogenase (SDH), also lead to elevated metabolite levels, which share 
the common feature of inhibiting α-KG-dependent enzymes31,33,34. This indicates, that 
metabolites like D-2-HG, as well as fumarate and succinate, are implicated in the 
dysregulation of cellular processes and have comparable roles in cellular 
transformation and oncogenesis. 
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Additionally, IDH1/2 mutant status or elevated D-2-HG concentrations, respectively, 
were associated with increased ROS-production. This is a consequence of mutant 
IDH1/2 consuming rather than producing NADPH11,35,36, which is used to regenerate 
the antioxidant glutathione. Therefore, mutIDH1/2 impacts the redox status of the cell, 
which is important with regard to possible DNA-damage by radicals37. Moreover, it was 
reported that elevated 2-HG concentrations cause a homologous recombination (HR) 
defect38, conferring chemosensitivity and radiosensitivity to patients with mutIDH1 
gliomas38. 
Further studies showed that treatment of the erythroblast cell line TF-1 with 200 µM 
trifluoromethyl benzyl (TFMB)-esterified D-2-HG caused growth factor independence 
and impaired differentiation39. Additionally, overexpression of D2HGDH was found to 
inhibit tumor growth in cells harboring mutIDH140. In contrast to slightly elevated 
D-2-HG levels from IDH1/2 mutation, which enhance proliferation in some cell line8, 
high D-2-HG concentrations are toxic. For example, the LD50 for D-2-HG in HEK293T 
embryonic kidney cells was determined to be 10 mM, while it was approximately 
50 mM in LN229 glioblastoma cells. Therefore, it is assumed that toxicity at high 
concentrations and an increased chemosensitivity are the reasons for a better 
prognosis of glioma patients with mutIDH1 compared to WT-IDH13,41. Regarding the 
prognostic impact of D-2-HG/ IDH1/2 mutation in AML patients, findings are 
contradictory so far42,43,44,45.  
A growing number of studies investigates the effects of D-2-HG on the tumor 
environment, for instance in promoting immune escape. I contributed to a study 
investigating the impact of D-2-HG on T-cells46. First of all, it was confirmed by 
analyzing cell extracts by LC-MS/MS, that T-cells take up D-2-HG produced by 
mutIDH1/2 myeloblasts of AML patients. Furthermore, it was shown that D-2-HG 
altered T-cell metabolism towards oxidative phosphorylation. On a functional level, a 
higher frequency of regulatory T-cells and a reduced polarization of Th17-cells was 
observed. A similar study found that D-2-HG impairs differentiation of monocytes into 
dendritic cells with impaired capacity for T-cell stimulation (Hammon et al, manuscript 
in preparation). 
For gliomas, which have a different microenvironment, 2-HG also seems to have an 
impact on immune cells. MutIDH1/2 gliomas were found to have less immune 
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infiltration, namely lower accumulation of CD3+CD8+ T-cell in tumor sites, as a 
consequence of reduced chemokine production by glioma cells47. Additionally, it was 
reported that mutIDH1 glioma cells showed translational silencing of NK receptors 
(NKG2D), which activate NK- and CD8+ T-cells and mediate cytotoxicity. 
Consequently, those cells acquired resistance to NK cells48. In conclusion, these 
reports provide evidence that D-2-HG might be an immune-modifying factor. 
 
4.2 Aspects of enzymology 
In investigations on accumulation of 2-HG in different diseases, enzymes play an 
important role. There is on the one hand IDH1/2 which - by single amino acid 
substitutions - undergoes changes in its affinity towards its actual product (α-KG) 
resulting in the almost reverse reaction now using α-KG as a substrate11. Additionally, 
type and position of the amino acid substitution affect the amount of 2-HG formed8. On 
the other hand, D2HGDH mutation like in 2-HG-aciduria cause a decreased enzyme 
activity with subsequent reduced degradation of D-2-HG. Even intact D2HDH is a low 
capacity enzyme and is described as a metabolic repair enzyme characterized by high 
affinity towards its typically low concentrated substrate49. 
These findings were made by investigating enzyme kinetics, hence analyzing and 
comparing reaction rates, for instance in dependence on changed experimental 
parameters. A frequently used method here is an enzyme assay, where the velocity of 
an enzymatic reaction is calculated from the decrease in substrate or increase in 
product per time, respectively. This is based on the assumption that, under 
experimental conditions, the reaction is in a steady state according to the theory of 
Michaelis and Menten, which can be applied to many, but not all enzymes50,51 (see 
Figure 4). This state is given, when formation and breakdown of the enzyme-substrate-
complex is equal, but not limited by any compound involved in the reaction. Drawing 
such a curve must give a linear relationship, otherwise the curve does not reflect the 
initial reaction velocity v0 and a steady state52. If the total amount of enzyme is known, 
the turnover number of every single enzyme molecule at saturating conditions (called 
kcat) can be calculated. Likewise, turnover in catalyzing α-KG formation from isocitrate 
for WT-IDH1 (4.4x104 1/s) was found to be 1000 fold higher than for IDH1-R132H 
(37.5 1/s)11. Another characteristic value describing enzyme kinetics is the maximum 
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velocity vmax, which is also required for determination of kcat. Additionally, Km is the 
substrate concentration at half maximum velocity and often regarded as a measure for 
the enzymes´ affinity towards its substrate. However, this is only true in the case of 
rapid equilibrium for the substrate-enzyme-complex with product formation being the 
rate limiting step. For applying saturating conditions in assays, a concentration of 10-
100 fold Km is suggested52. 
Figure 4. Kinetics of an 
enzyme-catalysed 
reaction according to 
Michaelis and Menten. 
This theory says that the 
turnover rate can be 
determined when 
formation and breakdown 
of the enzyme-substrate-
complex (ES) are in 
steady state. Kcat can only 
be calculated when the 
enzyme concentration [E] 
is known. 
 
 
 
 
In establishing an enzyme assay, conditions should resemble physiological conditions 
as closely as possible to obtain sensitive and reliable data on kinetics. Several factors 
impact enzyme activity. For human enzymes, the optimum temperature usually is 
37 °C and reaction rates decrease at higher and lower temperatures. Another 
important factor is pH, where the optimum often reflects the typical pH of the cell 
compartment the enzyme is located in53,54. The pH as well as ionic strength of the 
assay buffer are essential for proper conformation and stabilization of the enzyme. 
Finally, reactions are often dependent on cofactors and counter-ions, which need to 
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be included into the assay buffer in non-limiting concentrations. Both reactions 
investigated in this thesis are redox reactions: the formation of 2-HG is a reduction, 
while its degradation is an oxidation. Consequently, enzyme assays include a redox 
equivalent. The endogenous co-factors are NADPH for IDH1/2 and FAD for D2HDH. 
In assay buffers, however, often artificial redox agents are included, which allow for 
higher reaction rates and, therefore, enhanced sensitivity, especially for low substrate 
concentrations. Once the optimal assay conditions have been identified, they need to 
be kept constant. The only compound, the concentration of which may be varied, is the 
substrate in order to create a Michaelis-Menten plot. The assay is usually started by 
the addition of substrate to the reaction mixture or any other compound obligatory for 
the reaction. A blank sample, which lacks one component, can provide information 
about unspecific noise or spontaneous degradation in the absence of enzyme52. 
The measurement of substrate decrease or product increase, respectively, can be 
accomplished by different methods. One way is to perform a colorimetric assay, which 
is especially appropriate for the detection of colored products. A technical variant of 
this approach is a fluorometric assay, which is more sensitive. One prominent example 
is detection of the fluorescent signal from NADH, which is also used for determining 
2-HG in different biological specimens (explained in detail in 4.3.3)55. Fluorescence 
plate readers can automatically and continuously measure over a defined time range, 
providing data for kinetic analysis. Like used for this thesis, the substrate/product 
concentration can also be determined by (hyphenated) MS analysis. This is a so-called 
stopped assay, as aliquots at different time points are taken and the enzymatic reaction 
needs to be stopped, e.g., by enzyme precipitation. The advantages of such an assay 
are higher sensitivity and specificity.  
The results of enzyme assays do not only provide information on enzyme 
characteristics but also on enzyme regulation. Non-competitive inhibition can be seen 
from reduced vmax, while a higher Km is indicative of competitive inhibition. Furthermore, 
there is allosteric inhibition, which is a more complex inhibition type and does not 
necessarily give a Michaelis-Menten kinetic. Allosteric enzymes typically have a low-
affinity and a high-affinity state, with an inhibitor or activator, respectively, changing the 
state by interacting with the enzyme. Feedback inhibition is one example for that 
regulation; here the end product of a metabolic pathway can downregulate the key 
enzyme to prevent product accumulation. Compounds interacting in that way, can only 
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be identified when included in the assay mixture. Besides, regulation can also take part 
via posttranslational modifications (PTM). These include covalent attachment of a 
functional group, most commonly phosphorylation. Conformational changes, 
introduced in this way, can for instance alter substrate binding and, therefore, catalytic 
activity. For detection of PTMs, further methods are necessary like isoelectric focusing 
(IEF), which unravels changes in the isoelectric point of proteins. In addition, MS-based 
proteomics of PTMs has shown the large extent of protein modifications. More detailed 
information is gained from modification-specific enrichment techniques, like phospho-
peptide enrichment, combined with advanced MS/MS methods56,57. Finally, many 
enzymes can be upregulated at the protein level to adapt catalytic capacity. This can 
be detected via western blot using an antibody specifically raised against the enzyme. 
For some proteins, there are also antibodies targeting the phospho-site, which can 
again be helpful in the analysis of modifications.  
 
4.3 Metabolomics by hyphenated MS-techniques 
4.3.1 Overview 
The analysis of metabolites comprising a systems´ metabolome58 is called 
metabolomics59. This term was coined based on the nomenclature of other “omics”-
techniques such as genomics, transcriptomics and proteomics. Together those 
techniques reveal the “omics cascade” with the metabolome being the closest to 
phenotype. The metabolome can be subdivided into further classes, such as amino 
acids, organic acids, lipids, which all have distinct chemical properties. Thus, no 
instrument platform is suitable to analyze all metabolites60 but metabolomics still relies 
on combining several instruments and analytical methods. Nuclear magnetic 
resonance (mainly 1H-NMR) is also being used in metabolomics61-63. Although 
1H-NMR comes close to being a universal detector, it does not allow for complete 
coverage of a metabolome due to its low sensitivity. In the early years of MS in 
metabolomics, often direct infusion was favored because of short run time. However, 
this entails several problems like high background especially when injecting complex 
samples, severe ion suppression and lack of isomer separation. Coupling of 
chromatography and MS can overcome many of these problems and often is able to 
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distinguish between isomers by chromatographic separation. Therefore, in 
metabolomics hyphenated mass spectrometry is more commonly used, but there are 
still some rare applications with direct infusion. 
The classical metabolomics approach is called fingerprinting or untargeted 
metabolomics, which entails the analysis of all detectable compounds preferably with 
high resolution mass spectrometers. From these complex data, metabolites 
differentially regulated between groups are identified. However, this approach only 
gives rise to semi-quantitative data. To confirm findings of metabolites differing in 
abundance between different conditions or specimens, an alternative metabolomics 
approach has to be applied, namely metabolic profiling also called targeted 
metabolomics (see below). 
Depending on the separation technique coupled to mass spectrometry, one can 
distinguish three main platforms: GC-MS, LC-MS and CE (capillary electrophoresis)-
MS. In GC-analysis the mobile phase is gaseous and, therefore, highly suited for 
volatile compounds. For polar compounds with insufficient vapor pressure, 
derivatization is necessary to rise volatility, increase thermal stability, and enhance 
detection. Derivatization commonly reduces polarity by performing alkylation, silylation 
or acetylation on polar functional groups. (Some derivatization strategies are explained 
in chapter 7). For ionization, classically EI (electron ionization) is the first choice, which 
is regarded as a hard ionization technique commonly causing extensive fragmentation. 
Hence, the molecular ion is often low abundant or not detectable. However, this can 
be helpful for identification and structure determination of unknown compounds. The 
most frequent GC-MS instrument is a GC-EI-qMS, with a quadrupole as mass 
analyzer. In general, GC-MS is a robust bioanalytical technique providing a high 
chromatographic resolution. 
In liquid chromatography the mobile phase is a liquid; for isocratic elution a solvent is 
used. Mostly, however, two solvents are employed for gradient elution to facilitate 
elution and to shorten run times. The stationary phase consists of silica-based or 
polymer particles, which can be modified to change polarity. Based on the type of 
stationary phase, one can distinguish between normal phase (NP)-LC, reversed phase 
(RP)-LC, and HILIC (hydrophilic interaction liquid)-chromatography. Polarity of the 
mobile phase is adapted to the stationary phase and the type of LC application. The 
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most frequently used method is RP-LC, which combines a non-polar stationary phase 
with polar mobile phases (e.g., water, methanol, acetonitrile) for analysis of less polar 
compounds. By derivatization of bare silica, like in normal phase, the polarity is 
reversed giving the name to this LC-subtype. The most frequently employed stationary 
phase consists of C18-alkane modified silica. Finally, HILIC is a valuable separation 
technique to analyze polar and even ionic compounds, using columns like in NP-LC in 
combination with rather polar RP like mobile phases (more details see chapter 4.3.3). 
The choice of technique is driven by the chemical properties (defining 
solubility/retention) of the metabolites of interest. 
The typical ionization technique used in coupling of LC to MS is electrospray ionization 
(ESI). Ionization procedure starts with formation of charged droplets at the end of a 
capillary electrode, which are reduced by evaporation of the solvent until a bare 
charged analyte remains in the gas phase. This type of ionization takes place at 
atmospheric pressure. It is regarded a soft ionization technique forming primarily 
quasi-molecular ions, but also for example adducts. Positive and negative mode 
ionization can be carried out by applying voltage of the respective polarity. Certainly, 
ESI also has some drawbacks, e.g., matrix effects, which have an irreproducible impact 
on signal intensity. These interferences arise from coeluting (matrix) components, 
which are assumed to compete with the analyte during ion formation causing ion 
suppression or even enhancement64,65. However, proper sample extraction and clean-
up as well as chromatographic separation can reduce those interferences and, 
thereby, enhance signal intensity65. Furthermore, mobile phase additives can also 
influence the formation of ions in the source. In this context more problematic modifiers 
like the ion pairing reagent trifluoroacetic acid might be exchanged by, e.g., formic acid, 
which causes usually less ion suppression66. Finally, internal standards can be used 
to control for matrix dependent variation in ion yield (see below). 
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4.3.2 Quantitative targeted MS-analysis 
Quantitative analysis means experimental determination of the absolute concentration/ 
amount of a set of pre-defined compounds. The set of analytes is usually limited to a 
certain compound class or metabolites and intermediates of an explicit pathway. This 
targeted analysis is called metabolic profiling and is often used to verify a hypothesis, 
generated on other preliminary data67. 
One instrument that is highly qualified for this targeted analysis is a LC-ESI-QqQ-MS. 
As the colloquial name, TripleQuad-MS, already implies this instrument has three 
quadrupoles (QqQ), which are arranged in line with the second quadrupole Q2 being 
the collision cell. The other two quadrupoles (Q1 and Q3) can be operated in different 
scan modes with Q1 and/or Q3 set to a fixed mass or used to scan a certain mass 
range, respectively. MRM-mode (multiple reaction monitoring) is the most prominent 
mode for quantification analysis due to its high sensitivity and a broad dynamic range 
(of three to five orders of magnitude)68. Figure 5 shows a scheme of the principle of 
MRM:  
 
Figure 5. Scheme of a Triple Quad-instrument operated in MRM-mode. The charged analytes, 
produced by the ion source, are focused to form a narrow ion beam entering the first 
quadrupole Q1. The voltage applied here is set to isolate the parent ion. Ions of other m/z-
values are deflected and leave the ion path. The parent ion is accelerated to Q2, where it is 
fragmented by collision with a collision gas (N2 or argon). Q3 is operated identical to Q1, now 
selecting for the product ion, which hits the detector. The mass range isolated in Q1 and Q3 is 
usually a window of 1 Da around the m/z-value of the target compound. The pair of precursor 
and fragment ions is called a transition. 
MRM mode benefits from a low signal-to-noise-ratio and increased selectivity. The 
scheme shows the process for one analyte. For a set of analytes, the process needs 
to be repeated iteratively. Such a cycle gives one data point for each analyte, which 
are summed up to re-build a chromatogram. For a reliable peak reconstruction, a 
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minimal number of 15-20 data points across the peak is necessary69. Therefore, the 
time spent on scanning one analyte (called dwell time) is limited. On the other hand, 
when the dwell time is too short signal quality will be impaired. To circumvent this issue, 
it is possible to divide the LC-run into windows/periods, where only transitions of 
analytes are measured that are expected to elute from the column in this time range. 
Depending on the instrument options scheduled MRM´s can be programmed with a 
specific window for each analyte. All acquisition parameters for each compound are 
optimized by measuring analyte standards during method development. 
Linear range of TripleQuad instruments (like with other LC-ESI-MS instruments) is 
limited at the ULOQ (upper limit of quantification) either by saturation at the detector 
or due to e.g. charge limitations in the ion source70. The LLOQ (lower limit of 
quantification) is mainly dependent on ionization efficiency. As mentioned before, 
matrix effects can drastically affect ionization and therefore cause an increase of LOQ 
in comparison to standard samples or a different biological matrix.  
This is one explanation, why response, hence the peak intensity in arbitrary units, does 
not allow for absolute quantification. Another issue is, for instance, analyte loss during 
sample preparation. These problems can be overcome by including an internal 
standard (IS). The internal standard can be a compound of similar chemical nature or 
a structural analogue. The best option, however, is a stable isotope labeled analogue, 
where the analyte and its corresponding isotopologue elute from the column at the 
same retention time and are only distinguished by their mass. Thus, the IS corrects for 
matrix effects and ensures high specificity. In practice, a known concentration of IS is 
spiked into the sample at the earliest possible stage during sample preparation. The 
ratio of the analyte area and the IS area (A analyte / A IS; also called response) is used 
to calculate the sample´s absolute concentration. Two approaches are distinguished: 
on the one hand, the stable-isotope dilution (SID) methodology71-73, where the ratio 
(A analyte / A IS) is multiplied with the IS-concentration to calculate the analyte´s 
concentration. On the other hand, a multipoint calibration curve can be constructed 
based on the response (y axis) and the ratio of analyte concentration and IS 
concentration (x axis)74,75. The disadvantage of the addition of stable isotope labeled 
standard is the high expense, especially for methods containing a high number of 
analytes, and the limited availability. 
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Furthermore, quantitative approaches exist also for GC-MS. A comparable way to 
MRM is SIM (selected-ion-monitoring-) mode, where the quadrupole of a GC-EI-qMS 
instrument is set to iteratively isolate ions of preselected m/z-values76,77. Here, again 
sensitivity is increased in comparison to a full-scan approach. Nevertheless, inclusion 
of an internal standard and a calibration curve are recommended for absolute 
quantifications. 
The FDA (U.S. Department of Health and Human Services, Food and Drug 
Administration) has provided a guide for method development and validation of 
bioanalytical, quantitative assays for the analysis of metabolites and drugs in biological 
matrices such as blood, serum, plasma, or urine78. This guide should ensure high data 
quality by monitoring accuracy, precision, selectivity, sensitivity, reproducibility, and 
analyte stability.  
 
4.3.3 Analysis of 2-HG in biological samples 
Quantification of 2-HG in biological samples can be achieved by enzymatic assays, on 
the one hand. As mentioned earlier, Balss et al. (2012) developed an assay where 
degradation of D-2-HG is coupled to a fluorescence reaction via a two-step reaction55. 
Purified 2-hydroxyglutarate dehydrogenase from A. fermentans expressed in E. coli 
converts D-2-HG into α-KG using NAD+ as a hydride acceptor. The produced NADH is 
used by diaphorase to produce the fluorescent Resorufin from its non-fluorescent 
precursor Resazurin. To perform this assay, a reaction solution containing all enzymes 
and cofactors is mixed with the sample and incubated for 30 minutes at room 
temperature. Fluorescence signal intensity is used to calculate D-2-HG concentrations 
from a standard curve acquired in parallel with standard samples of known D-2-HG 
concentration. This assay is applicable to the analysis of several specimens like cell 
culture supernatant, urine, or serum. Even deparaffinized and deproteinized FFPE-
material can be subjected to this assay. According to the authors, the LLOQ for this 
assay is 0.44 µM D-2-HG in tumor tissue and 2.77 µM in serum. The assay shows 
results comparable to determination by GC-MS up to a concentration of about 500 µM. 
Beyond this enzymatic assay, several (quantitative) methods using GC-MS or 
LC-MS/MS were published. Quite a few publications apply one of two frequently cited 
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enantioselective methods: Gibson et al.79 (1993, butylated diastereomers via GC-MS) 
and Struys et al.80 (2004, DATAN-derivatives via LC-MS). Both methods are 
enantioselective, as they were developed in context of 2-HG-aciduria, where it is 
necessary to distinguish between D- and L-2-HG for diagnosis of D-2-HGA or L-2-
HGA, respectively. Gibson et al. reported a derivatization regimen using D-2-butanol 
for esterification of carboxyl groups (under acidic conditions) and acetic anhydride for 
acetylation of hydroxyl groups. By addition of enantiomeric pure D-2-butanol 
diastereomers are formed, which can be separated on polar, non-chiral GC-columns. 
In this method GC is coupled to MS via chemical ionization and data are acquired in 
SIM-mode. This derivatization strategy was already applied by the Wadman group to 
determine the absolute configuration of urinary 2-hydroxydicarboxylic acids including 
2-HG2,81. However, Gibson et al. further established this approach as a quantitative 
method including isotope dilution using D,L-[3,3,4,4-D4]-2-hydroxyglutaric acid 
(prepared from D4-α-KG) as internal standard. Similarly, Janin et al. in 2014 used 
[1,2,3,4-13C4]-labeled 2-HG (prepared from [13C4]-α-KG) in a GC-QqQ-MS/MS 
method82. Here the linear range is from ~ 50 pmol to 400 nmol (which equals to 0.5 µM 
and 4 mM, respectively, in a 100 µL sample) with the LOD determined at 20 pmol. 
 
Figure 6. Derivatization of 2-hydroxyglutarate using D-2-butanol and acetaldehyde for 
enantioselective analysis. For the structure of the derivatization product see Figure 14. 
Struys et al. used DATAN (diacetyl-L-tartaric anhydride) for derivatization again 
yielding diastereomers of 2-HG, which could be separated within five minutes on a 
C18-HPLC column (Xterra, Waters)80.  Acquisition of MS-data was performed in MRM-
mode. Once more, D,L-[3,3,4,4-D4]-2-hydroxyglutaric acid (prepared from [D4]-α-KG) 
is included as stable-isotope labeled standard. This method is stated to be less time-
consuming and less expensive than the aforementioned method reported by Gibson 
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et al. Poinsignon et al. (2016) similarly used derivatization with DATAN in the context 
of IDH1/2 mutation to analyze AML-patient samples in a clinical setting, as well as in 
preclinical applications using cellular and tissue samples83. Here the linear calibration 
curve ranged from 0.34 µM to 135.04 μM. Moreover, this method was used in the 2-HG 
analysis of mutIDH1/2 samples in the context of intrahepatic cholangiocarcinoma (ICC) 
with a comparable LLOQ of ~0.2 µM84. Those recent publications have made use of 
now commercially available deuterated 2-HG ([2,3,3- D3]-(RS)-2-hydroxyglutaric acid). 
Additionally, Ward et al. (2010) reported a GC-EI-MS method based on the silylation 
of cell extracts with MTBSTFA (N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide)10. 
Derivatized samples were then injected onto a HP-5MS capillary column for non-chiral 
analysis. Here, no internal standard was included, and peak areas were normalized to 
glutamate as relative measure of metabolite abundances. Therefore, this publication 
did not yield absolute quantitative values. It was rather used to check for drastically 
increased 2-HG levels in AML samples as marker for a mutation in IDH1/2. 
Many methods developed to detect elevated 2-HG levels due to mutIDH1/2 are not 
enantioselective, because the neo-enzymatic activity of IDH1/2 is specific for the 
production of D-2-HG. Thus, analysis of 2-HG may be accomplished directly by LC-
MS without derivatization. However, the hydrophilic nature of 2-HG impedes retention 
on classical, non-polar RP-LC-columns (e.g., C18). In addition, highly aqueous mobile 
phase conditions are required for solubilization and loading of 2-HG, which can cause 
phase collapse of traditional C18 columns. Modern C18 columns (e.g., Agilent, 
ZORBAX SB-Aq) can be operated with 100% water. Juratli et al. (2013) used such a 
column for the simultaneous quantification of TCA intermediates and 2-HG in low-
grade gliomas85. Detection was performed in MRM-mode and stable isotope-labeled 
internal standards were included for absolute quantification. 
Besides, methods using other types of LC-columns were developed, which regularly 
comprise several other metabolites. Fluorinated silica-based columns are an attractive 
alternative due to their effectiveness in retaining small polar molecules. Navis et al. 
(2013) used a Luna PFP column for analysis of D-2-HG by LC-MS/MS in MRM mode 
in specimens obtained from an IDH1-R132H mutation carrying xenograft model86. For 
absolute quantification, a 13C5-2-HG stable isotope solution was added to the sample 
before filtration to remove proteins. 
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Another means for increasing retention of charged analytes on reversed phase 
columns is the addition of an ion-pairing agent. Those agents are often non-volatile 
and, therefore, not compatible with online LC-ESI-MS. However, there are also volatile 
ion pair modifiers like tributylammonium acetate (TBAA), which was introduced into 
2-HG (and TCA) analysis by Dang 200911. Thus, a C18-column (Synergi Hydro-RP, 
Phenomenex) could be used in a LC-MS/MS approach, run on a TripleQuad instrument 
in MRM-mode. Quantification was achieved by comparison of peak areas with 
metabolite standards. However, experience in our laboratory showed that TBA is quite 
“sticky” and tends to remain in the chromatographic system causing serve 
interferences for methods using positive mode ionization and extensive flushing is 
required (K. Dettmer, personal communication). 
Finally, ion-exchange chromatography can be used for separation of charged 
compounds. However, high salt concentration is typically applied for elution. Therefore, 
this is not compatible for detection via MS, as most salts are non-volatile and impede 
ionization. Still, Borger et al. (2014) used a multiple-mode column (BioRad Fast Acid 
analysis) and isocratic elution with 0.1% formic acid in water87. Total run time was only 
four minutes. In this LC-MS/MS approach, the column was connected to a TripleQuad 
instrument operated in MRM-mode to quantify 2-HG in serum samples. Internal 
standard was again 13C5-2-HG, which was added before sample precipitation. 
Besides, hydrophilic interaction liquid chromatography (HILIC) is highly suitable for 
separation of polar and even ionic compounds like 2-HG. HILIC is a hybrid LC-method 
making use of polar stationary phases. Mobile phase - similar like in RP-LC - consists 
of a high percentage of an organic water-miscible solvent. But the gradient profile for 
HILIC is inverse to that of RP chromatography, i.e., the highest water content (maximal 
~50%) is reached at the end of the run. Separation is achieved by partitioning of the 
analytes between the water-rich layer, which is formed on the surface of the polar 
stationary phase, and the water-deficient mobile phase88. Consequently, HILIC offers 
retention to hydrophilic compounds in contrast to classical RP-LC methods. Gelman et 
al. (2015) reported the use of HILIC for the analysis of 2-HG and glutamine89. The 
column used was an Acquity UPLC BEH Amide column (Waters) coupled to a 
QqQ-MS, again in MRM-mode. Becker-Kettern et al. (2016) also set up a HILIC 
method investigating total 2-HG, together with several organic and amino acids90. A 
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ZicHILIC SeQuant column was connected to a Q-Orbitrap-HRMS. External calibration 
curves ranged from 0.01 µM to 50 μM for each metabolite. 
In addition to mass spectrometric bioanalytical methods, various NMR-based 
investigations were performed to analyze 2-HG14,91. For glioma patients it is even 
possible to perform in vivo measurements via MRT instruments. However, these 
investigations suffer from low sensitivity and a high background signal. Information on 
spatial metabolite distribution is also gained from analysis of tissue sections. Volexen 
et al. (2016)92 developed a bioluminescence assay for this purpose, Longuespee et al. 
(2018)93 used MALDI-TOF to examine tissue sections. 
In conclusion, it can be stated that numerous methods were published for 2-HG 
analysis, none of which is universally applicable. Each has its strengths but also 
shortcomings, which determine the usability of the method in the respective context. 
4.3.4 Flux/tracing analysis 
The metabolic flux of a cell is regarded as the metabolite amount that is converted in 
a certain time, i.e., the intracellular metabolic rate94. Flux or tracer analysis are two 
methods aiming to answer questions about cellular metabolic pathway (activity) and 
nutrient contribution. In contrast, quantitative data provide only a snapshot of 
metabolism at a given time point, but together with uptake and secretion rates it can 
be used to generate knowledge about a biochemical network. Metabolic flux data are 
generated by feeding a stable isotope labeled compound, named tracer, to the model 
system and samples are subsequently analyzed via hyphenated MS or NMR. All 
metabolites that are produced from the tracer, show an altered mass distribution due 
to the incorporated label, which can be made visible by MS-measurements. However, 
metabolic flux data are very complex and require computational data interpretation to 
calculate absolute pathway activity. Furthermore, the biological system, e.g. a cell, 
needs to be in a state without changes in flux and metabolite concentrations (metabolic 
steady state95) and in isotopic steady state, which means that the label enrichment in 
the metabolite of interest (=tracee) is stable96. These conditions require continuous cell 
culture to avoid limitations in nutrients, increasing cell density and therefore changes 
in proliferation rate. Furthermore, incubation times until isotopic steady state is 
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reached, differ based on the intermediates/pathways as well as the cell type and are 
dependent on the tracer used97. 
A much easier, though less informative approach, is tracer analysis, where the labeling 
patterns of cellular metabolites after incubation with a labeled precursor are interpreted 
directly97. Yet, change in flux should be minimal within the experimental time (ideally 
metabolic steady state, practically pseudo-steady state). This can be assumed for most 
pathways (e.g. glycolysis) in monolayer cell culture or suspension cells, when 
performing the tracer study as long as the cells are in the exponential growth phase98. 
Interpretation of such labeling pattern can give insights into relative pathway activity 
and contributions, in context of mutations or changes, which were evoked by 
administration of a metabolically active drug. 
Tracer analysis provides labeling patterns in all compounds involved in the metabolism 
of a labeled nutrient. The mass isotopomer distribution vector (MID) contains all 
fractional abundances of each isotopologue (M+0 to M+n; n is the analytes´ maximal 
labeled isotope number, introduced by the tracer, e.g. M+6 for 13C6-citrate) normalized 
to the sum of all possible isotopologues99. Therefore, these labeling patterns are 
independent of pool size and can unravel increased flux while absolute concentrations 
stay the same. Metabolites with identical patterns are in complete exchange. MIDs do 
not contain information on the position of label within the molecule. This can be 
determined by further experiments using NMR or by interpreting specific fragments 
from MS/MS-analysis.  
Another important measure in 13C-tracer analysis is mean isotopic enrichment (also 
called fractional contribution), which determines the fraction of a metabolite’s carbon 
that is produced from a certain nutrient. The mean isotopic enrichment is calculated as 
follows: 
𝑀𝐸 =
∑ 𝑖∗𝑠𝑛𝑖=0
𝑛
, 
where n is the number of carbon atoms in the metabolite, i denotes the isotopologues 
and s the relative fraction of the isotopologues as calculated in the MID100. Prerequisite 
is, that the tracer is fully 13C-labeled. Especially glucose and glutamine as the main 
carbon sources are well suited for tracer analysis. Summing up, the mean isotopic 
enrichment for those two (calculated from two independent experiments) is often close 
to 100%. If not, another substrate contributes to the formation of the tracee. For 
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instance, it was reported for different cells that under hypoxic conditions acetate 
contributes to fatty acid synthesis101.  
With focus on glycolysis and TCA cycle, commonly fully labeled compounds are used. 
Lactate can be formed from glycolysis and via pentose phosphate pathway. These two 
alternative routes can be distinguished by using 1,2-13C2-glucose as tracer102. This 
example shows that the choice of the tracer is dependent on the pathway of interest. 
Besides 13C-labeled nutrients, also tracers containing further stable isotopes like 15N 
or 2H are sometimes supplemented to cell culture media103,104. Nevertheless, 
13C-labeled compounds are the most frequently used. 
Cellular compartmentalization can influence the labeling pattern too. An established 
example here is pyruvate, which is found in both cytosol and mitochondria. A cell´s 
average labeling pattern cannot resolve the cellular distribution of pyruvate. However, 
it was found that the labeling pattern of alanine reflects mitochondrial pyruvate, while 
lactate is a cytosolic product of pyruvate97. 
Once the tracing data has been acquired, it needs to be subjected to correction for 
natural abundance of heavy isotopes introduced by the tracer. For instance, 13C has a 
natural abundance of 1.07 % contributing mainly to the M+1, but to a lower extent also 
to all other isotopologues. This correction is complex, nevertheless can be 
accomplished by using tools available from different sources (e.g. IsoCor105, 
IsocorrectoR106). Additionally, some bias is potentially introduced by derivatization, 
e.g., silylation (28Si 92.23 %, 29Si 4.68 %, 30Si 3.08 %). 
In conclusion, tracer analysis and to an even larger extent flux analysis are valuable 
tools for investigations on metabolism and alternative pathways. Nevertheless, this 
technique hides several pitfalls and therefore requires careful handling to avoid 
misinterpretations.  
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5 Methods and Material 
5.1 Materials 
D- and L-2-hydroxyglutarate, R- and S-5-oxotetrahydro-2-furancarboxylic acid, as well 
as pyridine, methyl chloroformate (MCF), and methoxylamine hydrochloride were from 
Sigma-Aldrich (Taufkirchen, Germany). Formic acid, methanol and ethyl acetate 
(LC-MS grade) from BDH Prolabo (VWR International, Vienna, Austria). N-Methyl-N-
(trimethylsilyl)-trifluoroacetamide (MSTFA) was purchased from Macherey-Nagel 
(Dueren, Germany).  
In all experiments purified water from a PURELAB Plus system (ELGA LabWater, 
Celle, Germany) was used. 
 
5.2 Biological samples 
5.2.1 Cell culture 
For this thesis the following cell lines were cultured using the listed conditions: 
HT1080 (a fibrosarcoma line; ATCC CCL-121, ATCC, Manassas, VA, USA) were 
cultured in DMEM (PAN, Aidenbach, Germany) supplemented with 10 % fetal calf 
serum (FCS, Biochrom AG, Berlin, Germany), 1 % penicillin-streptomycin (PAA, 
Pasching, Austria), and 2 mM L-glutamine (PAN). The HCT116 panel (colon 
carcinoma; Horizon Discovery, Waterbeach, UK; HD 104-013, HD 104-019, HD 104-
020) consists of a parental line (WT-IDH1/2) and three cell lines carrying the mutations 
IDH1-R132H, IDH2-R172K, and IDH2-R140Q, respectively. This panel was cultured in 
RPMI (1640, PAN), supplemented with 10 % FCS, 1 % penicillin-streptomycin, and 
2 mM L-glutamine. The same medium was used for cultivation of the LS174T-cell panel 
(colorectal adenocarcinoma, kindly provided by M. Kreutz, Regensburg) and CCRF-
CEM-C7H2 (acute lymphoblastic T-cell line; kindly provided by R. Kofler, Innsbruck, 
Austria). The breast cancer cell line MCF7 (ATCC HTB-22) was cultured in DMEM 
supplemented with 10 % FCS, 1 % penicillin-streptomycin and 2 mM L-glutamine. The 
MCF7 cells formed clusters after trypsinization and, therefore, could not be counted, 
but sub-cultured and seeded based on ratios. All other cells were counted using the 
Casy TT System (OLS OMNI Life Science, Bremen, Germany). 
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Adherent cells were sub-cultured by trypsinization, while suspension cells were diluted 
in fresh medium and once a week centrifuged (800 rpm, 5 min) to completely remove 
the old medium. Cells were sub-cultured two or three times a week and incubated at 
37°C, 5 % CO2. 
For experiments with treatment of cells, adherent cells were seeded into 6-well plates 
the day before treatment was started. Cell count was 0.25-0.5106/ well but was 
adapted to the intended incubation time. 
TRACER ANALYSIS 
Cells were seeded into plates and kept under standard conditions overnight. The next 
day, the medium was replaced with RPMI (+10% FCS, 1% P/S, +2 g/L glucose, w/o 
L-glutamine) supplemented with 2 mM 13C5-L-glutamine (CIL, Andover MA, USA), for 
glucose tracing with RPMI (+10% FCS, 1% P/S, w/o glucose, +2 mM L-glutamine) 
supplemented with 2 g/L 13C6-D-glucose (CIL), respectively. Cells were incubated for 
24 h or 48 h. Sample collection and extraction were performed using the routine 
protocol, but without addition of internal standard solution(s). 
OCTYL-2-HG 
Cells were seeded into plates and kept under standard conditions overnight. The next 
day, the medium was replaced with medium supplemented with (2R)-2-hydroxyglutaric 
acid octyl ester (Toronto Research Chemicals, Toronto, Canada). For control cells, the 
medium was replaced with fresh standard medium. Cells were incubated for 24 h. 
Sample collection and extraction were performed using the routine protocol. 
5.2.2 Serum samples 
Serum samples were collected at the Department of Internal Medicine III at the 
University Hospital Regensburg. Written informed consent was obtained from all 
participants. The study was approved by the local ethics committee and registered in 
the national registry for clinical studies (05-097). Serum was stored at -80°C until 
sample preparation, which was an extraction by methanol precipitation (see chapter 
5.4.1). 
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5.2.3  Glioma tissue samples 
With approval by the Ethics Committee of the University Medical Center Regensburg, 
Germany (10-248-0219), and written informed consent by the patients, frozen biopsies 
of human glioblastoma multiforme of known IDH mutational status were provided by 
the Department of Neurosurgery at the University Hospital Regensburg. The frozen 
tissues were immersed immediately into liquid nitrogen and stored at −80°C for a 
minimum of 24 h until sample preparation. For tissue homogenization, 30-120 mg of 
frozen tissue were transferred to Precellys 2 ml cups (pre-filled with 1.4 mm ceramic 
beads, Bertin Technologies, Montigny-le-Bretonneux, France), spiked with 40 µl 
internal standard (20 µl for smaller sample sizes) and covered with 1000 µl of 80% ice-
cold methanol followed by two cycles of homogenization using a Precellys 
homogenizer (Peqlab Biotechnologie GmbH, Erlangen, Germany). Metabolite 
extraction was performed similarly to chapter 5.4.1: tissue homogenates were washed 
twice with 500 µl 80% methanol and additionally washed with 600 µl H2O. After drying 
in the evaporator, samples were reconstituted in 200 µl H2O (100 µl for smaller sample 
sizes) prior to LC-MS/MS measurements (see chapter 5.5.1). Metabolite 
concentrations in tissue extracts determined by LC-MS/MS analysis were normalized 
to tissue weight. 
 
5.3 Enzyme assays 
For enzyme assays, pellets of trypsinated cells were washed twice with PBS 
(phosphate buffered saline) to remove excreted protein and FCS. Cells were lysed in 
the respective assay buffer by sonication on ice, followed by centrifugation at 10.000 xg 
at 4°C for 5 min to remove cellular debris. The supernatant comprises the lysate used 
for the assay. An aliquot is taken to determine protein content for normalization. 
For assaying D2HDH activity the buffer consisted of 20 mM HEPES, 25 mM KCl, 
0.05 mM ZnCl2, and protease inhibitor cocktail. To start the assay, the lysate is spiked 
with D-2-HG (various concentrations, as stated) and 2 mM PMS (phenazine 
methosulfate) as redox equivalent. For control, buffer without lysate was incubated with 
the same concentrations of D-2-HG and PMS. Incubation was performed under gentle 
shaking (400 rpm) at 37 °C. Aliquots of 20 µL were taken over a period up to 5 hours 
and mixed with stable isotope-labeled standard ([2,3,3]-D3-2-HG, C/D/N Isotopes Inc., 
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Pointe-Claire, Canada; 100 μM in water). Precipitation with ice-cold methanol stopped 
the enzymatic reaction. After extraction, samples were analyzed by LC-MS/MS.  
For assaying D-2-HG production by mutIDH1/2, assay buffer consisted of 50 mM 
Tris-HCl (pH 7.4), 10 mM NaCl, 2 mM MgCl2 and protease inhibitor cocktail (adapted 
from Pusch8). Here, the assay was started by addition of α-ketoglutarate and 
10 mM NADPH. The following steps were identical to those for the D2HDH assay. 
 
5.4 MS-sample preparation  
5.4.1 Methanol precipitation and sample extraction 
Samples analyzed for this thesis included serum or plasma, cell pellets and 
supernatant. For most analyses, it was necessary to remove the protein, which was 
done by methanol precipitation, which at the same time stopped any metabolic activity. 
For liquid samples like serum, plasma and cell culture supernatant, usually 50 µL- 
aliquots were precipitated in 200 µL 100 % cold methanol (MeOH). For quantitative 
analysis, the respective (stable isotope labeled) internal standard was added before 
methanol precipitation. Suspension cells were pelleted by centrifugation; supernatants 
were collected separately and treated as described above. The pellet was thoroughly 
washed three times with PBS to remove metabolites sticking to the outer surface of 
the cells, before addition of internal standard and protein precipitation with 80 % cold 
MeOH. For adherent cells the medium was collected and treated as described above. 
Cells in the well were washed three times with PBS, before the internal standard was 
added followed by scrapping the cells in 80 % cold methanol (600 µL are used for wells 
of a 6-well plate). The well is washed with additional 400 µL MeOH and combined with 
the first precipitate. All precipitates were further processed by pelleting the precipitated 
protein at 9560 xg, 4°C, 5 min and two further washing steps using 80 % (cell pellets) 
or 100 % MeOH (liquid samples), respectively. The methanolic phase, containing the 
analytes, was collected and combined in glass vials. Samples were dried using an 
infrared vortex vacuum evaporator (CombiDancer, Hettich AG, Baech, Switzerland). 
Further processing is dependent on the respective MS-method. 
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5.4.2 Derivatization for GC-analysis 
For GC-analysis, dried sample extracts or dried medium (10 µL) residues were 
subjected to derivatization as previously described (Dietl et al. 2009107). The protocol 
includes methoximation (using methoxylamine hydrochloride in pyridine) and silylation 
(with N-methyl-N-trimethylsilyl-trifluoroacetamide MSTFA, Macherey-Nagel). The 
derivatization is carried out by an MPS-2 Prepstation sample robot (Gerstel, 
Mülheim/Ruhr, Germany) for automated sample handling. 
For tracer analysis of 2-HG/-lactone and other metabolites, derivatization needed to 
be adapted to avoid interconversion of 2-HG/-lactone. Therefore, dried sample extracts 
were subjected to a two-step incubation regimen consisting of addition of MSTFA 
followed by incubation with methoxylamine hydrochloride in pyridine (as proton 
acceptor). Ten μL of a 1 mM undecanoic acid solution in isooctane were added to the 
dried residues as retention and injection standard. Silylation was carried out by the 
addition of 25 μL of MSTFA, and incubation for 30 min at 60°C. Then 25 μL of 
20 mg/mL methoxylamine hydrochloride in pyridine were added to the sample and 
incubated at 60°C for 30 min. Finally, the sample was diluted further with 25 µL MeOx-
reagent. Derivatization was carried out fully automated on the MPS-2 Prepstation 
sample robot. 
Further attempts to establish derivatization of 2-HG and its lactone are summarized in 
chapter 7. 
5.4.3 PCF-derivatization for amino acid analysis 
For amino acid analysis, derivatization with PCF (propyl chloroformate) was performed 
to increase retention of these polar compounds on a C18 column. Dried cell pellet 
extracts were reconstituted in 100 µL of water of which 10 µL were subjected to PCF-
derivatization for amino acid analysis (as described in van der Goot et al. 2014108). For 
medium 5-10 µL were directly used for derivatization. Internal standard mix contained 
a commercially available Amino Acid Standard Mix (Cambridge Isotopes, MSK-A2-1.2) 
spiked with D7-ornithine (Cambridge Isotopes), L-tryptophan-D5) (Eurisotop, Saint-
Aubin, France), U13C5-glutamine (Cambridge Isotopes), 13C4,15N2-L-asparagine 
(Cortecnet, Voisins-Le-Bretonneux, France), and D5-hippuric Acid (Biozol, Eching, 
Germany), to yield a concentration of 1 mM for each labeled compound. Ten µL of a 
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1:10-dilution of this standard mix were added to cell pellets before methanol 
precipitation, and a 1:100-dilution was added to medium samples directly before PCF-
derivatization. After derivatization, derivatives were extracted with ethyl acetate, dried 
under a nitrogen stream and reconstituted in 100 μL water/methanol (38%/ 62%, v/v). 
 
5.5 MS methods 
5.5.1 2-HG/-lactone quantification by HPLC-MS/MS 
For analysis of 2-HG/-lactone, samples were reconstituted in 50 µL ddH2O and 
transferred into a glass insert. HPLC-MS/MS analysis was performed as described in 
Voelxen et al. 92 and Berger et al. 109. Briefly, HPLC-MS/MS analysis was achieved 
using a HPLC (Agilent 1200, Waldbronn, Germany) coupled to an API 4000 QTRAP 
(AB SCIEX, Darmstadt, Germany) operated in negative ionization mode. The HPLC 
column used was a Discovery HS F5-3 HPLC column (15 cm x 2.1 mm, 3 µm; Supelco, 
Bellefonte, USA) equipped with a Security Guard column (C18, Phenomenex, 
Aschaffenburg, Germany) and kept at 30°C. Gradient elution was achieved with mobile 
phase A consisting of 0.1 % formic acid in water (v/v) and 100 % acetonitrile as mobile 
phase B. The gradient for chromatographic separation started with 0 % B, 200 µL/min, 
increased to 100 % B from 6.50 min to 8 min at 350 µL/min, and stayed at 100 % B for 
2 min, followed by a reconditioning of the column at the starting condition for 8 min. An 
injection volume of 5 μL was used. Detection was performed in MRM-mode using the 
following ion transitions: m/z 147.1 [M-H]- to m/z 84.8 for 2-HG, m/z 150.1 [M-H]- to m/z 
87.8 for 2-HG-D3 and m/z 128.8 [M-H]- to m/z 100.8 for 2-HG-lactone, m/z 131.8 [M-H]-  
to m/z 87.9 for 2-HG-lactone-D3. Data analysis was done using the Analyst Software 
(version 1.6.2, AB Sciex). Quantification was achieved using a calibration curve with 
the area of target compounds normalized by the area of the corresponding stable 
isotope-labeled standard. 
5.5.2 Amino acid quantification and tracer analysis by HPLC-MS/MS 
Quantitative amino acids analysis was performed as described in van der Goot et al. 
(2014)108. Briefly, HPLC-MS/MS instrumentation was an Agilent 1200 coupled to an 
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API 4000 QTRAP (see above) operated in positive ionization mode. An EZ:faast AAA-
MS (250 × 3 mm i.d., 4 μm, Phenomenex) reversed-phase column was used and kept 
at 30 °C. Mobile phases A was 10 mM ammonium formate and 0.1 % (vol/vol) 
heptafluorobutyric acid in water and mobile phase B was 10 mM ammonium formate 
and 0.1 % (vol/vol) heptafluorobutyric acid in methanol. The gradient for 
chromatographic separation started with 62 % B, increased to 79 % B within 12 min, 
further increased to 98 % B within 0.01 min, and kept at 98 % B for 3 min before 
reconditioning of the column at the starting condition for 8 min. The column flow rate 
was 350 μL/min. Injection volume was 5 μL for cell pellet samples and 10 µL for cell 
supernatant. The MS/MS was operated in MRM using one transition each for the 
analyte and the internal standard. Quantification was performed using calibration 
curves. Data analysis was done using the Analyst Software (version 1.6.2, AB Sciex). 
For tracer analysis, MRM-transitions are programmed for all possible isotopologues 
and peak areas are used directly for data analysis. The R-package IsoCorrectoR was 
used to correct for natural abundance of 13C and other naturally occurring stable 
isotopes and for impurities of the tracer106. 
5.5.3 Organic acid quantification by GC-EI-MS 
For quantification of glucose and organic acids, a previously published method was 
used107. The internal standard mix contained 1 mM each of 13C3-pyruvate, 
[2,3,3]-D3-malate acid, 13C4-succinate, 13C3-lactate, [2,2,4,4]-D4-citrate, 13C4-fumarate, 
and D6-α-ketoglutarate. Dried sample residues were subjected to derivatization using 
methoximation and silylation.  First, 50 μL of 20 mg/mL methoxylamine hydrochloride 
in pyridine were added to the sample and incubated at 60°C for 60 min, then the 
injection standard undecanoic acid (10 µL of 1mM solution in isooctane) was added 
followed by 50 µL MSTFA and incubation at 60°C for 60 min. The derivatization is 
carried out on an MPS-2 Prepstation sample robot (Gerstel, Mülheim/Ruhr, Germany). 
Derivatized samples were analyzed by an Agilent model 6890 GC (Agilent, Palo Alto, 
CA) equipped with a Mass Selective Detector model 5975 Inert XL. Chromatographic 
separation was carried out on an RXI-5MS column, 30 m x 0.25 mm i.d. x 0.25 µm film 
thickness (Restek, Bad Homburg, Germany), which was connected to a 2 m 
deactivated pre-column (Agilent Technologies, Palo Alto, CA, USA). A sample volume 
of 1 µL and an injection temperature of 280°C was used. Cell pellet extracts were 
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injected splitless (splitless time 1 min), while medium samples were injected with a split 
ratio of 1:8. The initial oven temperature was set at 50°C, ramped at 5°C/min to 120°C, 
changed to 8°C/min up to 300°C, and held for 5 min. Helium was used as carrier gas 
at a flow-rate of 0.7 mL/min. Data analysis was done with Mass Hunter Quantitative 
Analysis Workstation Software (Agilent, version B.07.01). 
5.5.4 Organic acid tracer analysis 
Here, two different methods were used, which are explained in more detail in 
chapter 8.1.1.  
The first method comprised HPLC-ESI-MS/MS analysis using an Agilent 1200 SL 
HPLC and a 4000 QTRAP mass spectrometer. A Discovery HS F5-3 HPLC column 
(15 cm × 2.1 mm, 3 μm; Supelco) equipped with a Security Guard column (C18, 
Phenomenex) was used with mobile phase A consisting of 0.1% formic acid in water 
(v/v) and acetonitrile as mobile phase B. Gradient elution started with an isocratic hold 
at 0% B for 5 min and a flow rate of 300 μL/min, followed by a linear increase to 100% B 
in 2 min, which was held for 4 min. For equilibration, the solvent was changed back to 
0% B from 11 min to 11.1 min and held until 18 min. The flow rate was increased to 
350 μL/min at 11.1 min. The column was kept at 30°C, and an injection volume of 
10 μL was used. The mass spectrometer was operated in negative mode and detection 
was performed in MRM-mode using transitions for each metabolite.  
Furthermore, a tracer analysis by GC-APCI-TOF-MS was implemented (see chapter 
8.1.1). Sample derivatization consists of silylation followed by methoximation, as 
described in chapter 5.4.2. Instrumentation included a model 450-GC (Bruker 
Daltonics GmbH, Bremen, Germany) that was equipped with an autosampler (model 
PAL COMBI-xt from CTC Analytics, Zwingen, Switzerland) for sample injection with a 
10 μL Hamilton syringe. The GC was coupled to a microTOF mass spectrometer 
(Bruker Daltonics) via an APCI II source. For separation of analytes, an RXI-5MS 
column, 30 m x 0.25 mm i.d. x 0.25 µm film thickness (Restek) was used with a 2 m 
deactivated pre- and a 0.5 m post-column of matching inner diameter (Agilent). The 
GC parameters were identical to those for organic acid quantification on an Agilent 
model 6890 GC/ MSD 5975 Inert XL. A sample volume of 1 μL was introduced at 280°C 
performing hot needle splitless injection (preinjection dwell of 1 s) with a splitless time 
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of 1 min. Helium served as the carrier gas at a constant flow rate of 0.7 mL/min. The 
transfer line to the MS instrument was maintained at 290°C. The APCI II source was 
operated as follows: ionization mode, positive; drying gas (nitrogen) temperature, 
150°C; drying gas flow rate, 2.0 L/min; APCI vaporizer temperature, 300°C; nebulizer 
gas (nitrogen) pressure, 2.5 bar; current of the corona discharge needle, +4000 nA; 
capillary voltage, -3000 V; end-plate offset, -500 V. Data analysis was done with 
Compass QuantAnalysis software (Bruker, version 2.2). 
For tracer analysis, peak areas of all isotopologues are used directly for data analysis. 
The R-package IsoCorrectoR was used to correct for natural abundance of 13C and 
other naturally occurring stable isotopes and for impurities of the tracer106. 
5.5.5 Enantioselective analysis of D-/L-2-HG 
Enantioselective analysis was performed by GC-MS after chiral derivatization adapting 
a protocol by Gibson et al. (1993)79. Briefly, standard solutions or biological samples 
were dried under a nitrogen stream. The residues were re-dissolved in 50 µL of 
S-2-butanol (Sigma-Aldrich), acidified with 5 µL of 12 M HCl, and heated for 3 h at 
90°C. Samples were extracted with 500 µL of hexane and dried under nitrogen. For 
acetylation, 30 µL of pyridine and 30 µL of acetic anhydride were added to the residue 
and incubated for 1 h at 80°C. Again, samples were dried under nitrogen and 
re-dissolved in 50-100 µL of hexane. Analyses were performed on an Agilent 6890N 
GC equipped with a Mass Selective Detector Model 5975 Inert using a DB-Wax UI 
(Agilent; 30 m × 0.25 mm ID × 0.25 mm film thickness) column. The following 
parameters were used: injection volume 1 µL in splitless mode (splitless time 1 min), 
helium flow 1.0 mL/min, full scan mode from 50–600 m/z. The initial oven temperature 
was set at 50°C, ramped at 5°C/min to 245°C, and held for 10 min. Data analysis was 
done with Mass Hunter Qualitative Analysis Workstation Software (Agilent, version 
B.07.00). 
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5.6 LysoTracker staining 
The day before performing the staining experiment, cells were seeded at a density of 
0.2x106 cells/well on 24 mm cover glasses for microscopy in a 6-well plate aiming at 
scattered individual cells.  
On the next day, cells were incubated with LysoTracker Deep Red (Invitrogen - 
Thermofischer, Karlsruhe, Germany; 1:10.000) and Hoechst 33342-Dye (Invitrogen - 
Thermofischer; 1:300 from a 5*10-4 M stock solution) in standard medium for 30 min at 
37 °C. Prior to imaging, the medium was discarded and the cells were overlaid with 
colorless medium (without phenol-red). Glass coverslips were mounted and staged on 
an inverted microscope Axio Observer Z.1 (Carl Zeiss Microscopy GmbH, Jena 
Germany) equipped with a Fluar 40x/1.30 Oil M27 objective. Excitation wavelength 
was 622-655 nm for LysoTracker Red and 335-383 nm for Hoe33342 with emission 
light filtered at 665-715 nm and 420-470 nm, respectively. Images were acquired using 
Zen software (blue edition, 1.0.0.0, Carl Zeiss MicroImaging GmbH) 
For analysis, single channel images were exported as .tif files. Further processing was 
done with ImageJ (2.0.0-rc-43/1.51j, National Institute of Health, USA), which provides 
sum of stained area per image. Spots from Hoe-staining represents nuclei and is used 
to normalize lysosomal staining. 
 
5.7 Miscellaneous 
Western Blot and qPCR were performed as described in the experimental section of 
Berger et al.109. 
(Intracellular) metabolite concentrations were normalized to total protein content 
determined using the FluoroProfile® Protein Quantification Kit (Sigma-Aldrich) 
according to manufacturer’s instructions. Briefly, cell pellets and enzyme assay 
aliquots for protein determination were lysed in a sodium phosphate buffer (20 mM) 
with 1.2 % SDS. Samples were diluted in water when necessary. A calibration curve 
was generated using a BSA-standard solution (Sigma-Aldrich), which was diluted in 
water. The assay buffer was prepared from water, dye (FluoroProfile Fluorescent 
Reagent) and quantification buffer (25 % acetonitrile, 3 % SDS, 200 mM sodium 
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bicarbonate in water) (8:1:1). Later the dye was replaced by the fluorescent dye 
SERVA Purple (Serva, Heidelberg, Germany). Assay buffer and BSA-standard or 
(diluted) sample were mixed in equal amounts in a black 96-well plate (Greiner, 
Frickenhausen, Germany) and incubated for about 1.5 h. The assay is measured with 
a fluorimeter at an excitation wavelength of 485 nm and an emission wavelength of 
600 nm. 
 
5.8 Statistics 
Basic statistics were performed with MS Excel 2013. ANOVA, as well as post hoc-tests 
(Tukey´s HSD, Dunnett) were performed with R (version 1.1.383). Plots were prepared 
with Excel; data represent means and error bars standard deviations, if not stated 
otherwise. Bland-Altman-plots were created (using Excel) by plotting differences 
between measurements against the mean of measurements. For differences, normal 
distribution was assumed when found to be within mean differences ± 1.96*SD. 
For calculation of the Km-value for D2HDH, OriginPro 8 was used (hill function; n=1 for 
a single substrate model). Plots showing enzyme kinetics are generated based on 
these calculations by OriginPro 8. 
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6 Quantitative analysis of 2-HG/-lactone 
6.1 Development and validation of a quantitative LC-MS/MS 
method 
A quantitative LC-MS/MS-method for 2-HG&-lactone analysis was established to 
confirm the finding of 2-HG-lactone in serum extracts of AML-patients carrying an 
IDH1/2 mutation. In contrast to GC-MS analysis, entailing the risk of artefact detection 
from derivatization, LC-MS/MS benefits form a straightforward sample preparation, 
namely methanol precipitation. Quantification of 2-HG and 2-HG-lactone was achieved 
by running an LC-ESI-QqQ-MS method. Detection was performed in MRM mode using 
the following ion transitions: m/z 147.1 [M – H]- to m/z 84.8 for 2-HG, and m/z 150.1 to 
m/z 87.8 for 2-HG-D3, as well as m/z 128 [M – H]- to m/z 84.8 for 2-HG-lactone and 
m/z 131 to m/z 87.8 for 2-HG-lactone-D3. This analysis yielded two well resolved 
peaks, one each for 2-HG and its respective lactone (Figure 7). Chromatographic 
separation of the two compounds was found to be necessary, as 2-HG, due to the loss 
of H2O during ionization, yielded a signal for the transition of 2-HG-lactone. But the two 
compounds could be distinguished readily based on their different retention times. 
However, this non-chiral method is not able to separate D- and L- enantiomers.  
 
Figure 7. Representative 
chromatograms (EICs of 2-HG&-
lactone) of a standard (upper panel) 
and serum sample of an AML patient 
with IDH(1-R132L) mutation (lower 
panel). 2-HG elutes at RT 4.4 min, 
2-HG-lactone at RT 8.2 min. The 
peak at RT 6.0 min is due to an 
unidentified matrix compound. 
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Calibration curves were calculated from the area ratios of analyte and stable isotope 
labeled standard in pure standards, applying a 1/x-weighing. Internal standard solution 
consisted of [2,3,3]-D3-2-HG (C/D/N Isotopes Inc.), which was incubated with HCl at 
100°C for 30 min to form the 2-HG-lactone-D3. This solution was evaporated to 
complete dryness and re-suspended in ddH2O to yield a final concentration of 100 μM 
2-HG-D3 and 2-HG-lactone-D3. Ten µL of this internal standard were added to the 
sample before precipitation, unless stated otherwise. Table 1 summarizes 
characteristic parameters established for this targeted LC-MS/MS analysis from pure 
standards in water and cell culture samples. 
 
Table 1. Figures of merit for the LC-MS/MS method employed for quantification of 
2-HG&-lactone. Mean accuracy was calculated from blank medium spiked with 2-HG in known 
concentration. Precision was calculated from repeated injections. Recovery represents relative 
amount of 2-HG  contained in extracted samples (medium with and without FCS) in comparison 
to known concentration used for spike-in (three levels), that represent 100% recovery. 
(r=correlation coefficient for calibration curve). (This table is partially reproduced from Berger 
et al.109) 
 2-HG 2-HG-lactone 
LOD (S/N>3) < 0.05 µM  < 0.05 µM 
LLOQ 0.2 µM 0.3 µM 
ULOQ 900 µM 1000 µM 
r > 0.9988 > 0.9995 
internal standard D3-2-HG D3-2-HG-lactone 
Accuracy/precision from spike at 3 levels (n=5) 
0.5 µM 97.8 % ± 5.7 95.9 % ± 7.1 
25 µM 100.8 % ± 1.5 103.2 % ± 3.2 
500 µM 97.7 % ± 2.0 95.8 % ± 1.4 
Recovery (n=6) from cell culture media +FCS, -FCS 
0.5 µM 101.8 %, 107.7 % 100.1 %, 110.8 % 
25 µM 118.6 %, 125.5 % 110.8 %, 114.1 % 
500 µM 111.9 %, 120.1 % 101.3 %, 114.4 % 
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Samples analyzed by means of this LC-MS/MS-method included extracts of serum, 
tissue and both cell pellets and supernatant. Figure 7 shows exemplary 
chromatograms of 2-HG/-lactone analysis in standard and AML-serum. For samples 
with an IDH1/2 mutation background, the values were assumed to reflect the 
D-enantiomers. Some enantioselective test measurements with extracts from HCT116 
and HT1080 cells confirmed this assumption (Supplemental Figure S1). 
 
6.2 Enzymatic assay to measure degradation of D-2-HG 
As mentioned earlier, D-2-HG produced in certain cancer cells carrying an IDH1/2 
mutation is accumulating to high levels and is therefore regarded as an 
oncometabolite. In contrast to 2-HG-aciduria, where the degrading enzyme D2HGDH, 
is mutated, it is supposed to be fully active in cells with IDH1/2 mutation. However, it 
was never investigated on an experimental basis, whether this is really the case and 
how D2HDH activity might be regulated in response to elevated levels of its substrate. 
As part of this thesis, experimental evidence was collected on this issue and published 
in 2019 (Berger et al.109). This chapter summarizes the results of this study: 
A cell-based assay was developed with concomitant 2-HG quantification by 
LC-MS/MS. The work-flow of the assay is explained in a schematic representation 
(Figure 8). 
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Figure 8. A cell-based enzyme assay 
was established to measure the rate 
of oxidation of D-2-HG to 
-ketoglutarate by D2HDH. First, 
cells were sonicated in an assay 
buffer containing a redox reagent. 
Enantiomerically pure D-2-HG was 
added, as the LC-MS/MS method 
employed was not enantioselective. 
Then, lysate was incubated at 37°C 
with gentle shaking for up to several 
hours. Aliquots were taken repeatedly 
over this time period and enzymatic 
reaction was stopped by methanol 
precipitation. Aliquots were extracted 
and subjected to LC-MS/MS to 
determine 2-HG concentration. 
For calculation of degradation rates, only values within the linear range were used. 
This assay was optimized regarding the assay buffer composition: FAD (flavin adenine 
dinucleotide), as the endogenous redox partner, was compared against other artificial 
redox agents, namely INT (iodonitrotetrazolium) and PMS (phenazine methosulfate). 
The latter showed the significant highest degradation rates and was therefore chosen 
to ensure maximal sensitivity. pH of the buffer was also investigated and found to be 
optimal at pH 7.6, which reflects mitochondrial pH, the compartment D2HDH is located 
to. 
As explained earlier, in enzymatic assays it is also possible to follow the product of the 
enzymatic reaction under investigation. In the case of D-2-HG degradation, the 
product, α-ketoglutarate, was not a favorable analyte. With an established GC-EI-qMS 
method (see chapter 5.5.3) including also α-KG, it was not possible for assay aliquot 
to get values above the LLOQ. α-KG is a rather low abundant metabolite which is 
substrate to many enzymes. Activity of those enzymes, while performing the D-2-HG 
degradation assay, cannot be excluded, although co-factors etc. might be limiting as 
not supplied in surplus. With this in mind, it was assumed that D-2-HG, which in 
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humans - to the best of my knowledge - is only substrate to D2HDH, is the more reliable 
analyte. Furthermore, it was assumed, that after addition of D-2-HG in surplus to the 
cell lysate, degradation of total 2-HG equals to D-2-HG. A test measurement of assay 
aliquots from MCF7 cell homogenates using a chiral method (according to Gibson79) 
showed that this assumption is valid (Figure 9). 
Figure 9. Enantioselective analysis of 2-HG 
degradation in aliquots of MCF7 
homogenates. The assay was started by the 
addition of D-2-HG (>95% purity). Data 
points represent three pooled replicate 
aliquots. Degradation rate of D-2-HG agrees 
well with 2-HG data from LC-MS/MS 
analysis. Figure reproduced from Berger et 
al109. 
The assay was applied to lysates of MCF7 cells to determine the Km-value. D2HDH in 
these cells has a Km of 26.4 µM (standard error 1.65, R2adj=0.99718; n=3 per data point, 
two independent experiments; Figure 10), which is similar to published results from 
other mammalian cells110,111, but different from Arabidopsis thaliana (~580 µM)26. 
Furthermore, this rather low Km is in line with the suggestion that D2HDH is a metabolic 
repair enzyme, acting already at low substrate concentrations. We additionally found 
that other cell lines, like HT1080 cells, show different enzyme kinetics as vmax of those 
cells was lower compared to MCF7. This is especially interesting as HT1080 cells carry 
an IDH1-R132C mutation and therefore have elevated D-2-HG levels in comparison to 
WT-IDH1/2 cell like MCF7.  
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Figure 10. Analysis of D-2-HG degradation in several cell lines. A) The described D2HDH-
assay was applied to homogenates of MCF7 cells, and established a Km-value of 26.4 µM 
D-2-HG. B) Degradation capacitiy was found to differ between cell lines tested, but this was 
not reflected in protein abundance of D2HDH as measured by Western Blot (C). Figure 
reproduced from Berger et al109. 
MCF7 cells were treated with 1 mM or 5 mM D-2-HG for both 24 h and 48 h, 
respectively, to check for D2HDH regulation in response to this treatment. However, 
significant differences between treated and untreated MCF7 cells neither in the 
enzyme assay, nor on protein or mRNA level of D2HDH expression could be observed 
(Figure 11). To investigate long-term effects of D-2-HG, we took cells from the HCT116 
panel, comprising the parental HCT116 cell line with WT-IDH1/2 and cell lines with the 
following mutations: IDH1-R132H/+, IDH2-R172K/+, and IDH2-R140Q /+. These 
mutated cells produce endogenous D-2-HG and show similar levels to HT1080 cells. 
However, regulation of D2HDH activity and expression does not give a clear picture. 
For the enzyme assay, results show a high variance making a fit of the Michaelis-
Menten-kinetic impossible. Protein expression in the HCT116 panel is found to be 
higher compared to MCF7 cells, but within the panel only HCT116 IDH2-R140Q is 
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significantly higher (ANOVA p=0.028, Tukey´s HSD parental vs IDH2-R140Q: 
padj=0.032). Together with data from several publications this hints at a more complex 
regulation of D2HDH on the protein level31,46,112. 
 
Figure 11. MCF7 cells were treated with 1 mM and 5 mM D-2-HG for 24 h and 48 h (including 
a control without treatment). Comparison of D2HDH activities (A&B) did not show significant 
differences (24 h: ANOVA p=0.779; 48 h: ANOVA p=0.069). Protein abundance of D2HDH 
was measured by Western Blot (C&D) and did not uncover significant changes (24 h: ANOVA 
p=0.505; 48 h: ANOVA p=0.069). Figure reproduced from Berger et al109. 
Finally, we compared D-2-HG degradation by D2HDH to production of D-2-HG by 
mutIDH1/2, both measured in cell homogenates from HCT116 cell panel. Buffer 
composition for mutIDH1/2 assay was adapted according to a protocol from the Pusch 
lab8. Both assays were run close to saturating substrate concentrations and after 
addition of the endogenous redox partner, which is FAD for D2HDH and NADPH for 
IDH1/2. Under these experimental conditions, which are supposed to reflect 
physiological conditions in mutIDH1/2 cancer cells, D-2-HG production clearly 
exceeded its degradation (Figure 12). 
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Figure 12. Comparison of 
D-2-HG production by 
mutIDH1/2 (using 1 mM or 
10 mM α-KG as substrate) with 
its degradation (100 µM) by 
D2HDH in HCT116 IDH1-
R132H (A) and HCT116 IDH2-
R172K cells (B). Both reactions 
run approximately at maximal 
velocity, but production clearly 
exceeds degradation. C) shows 
enzymatic 2-HG production 
capacity in cell homogenates 
reflecting 2-HG production by 
the HCT116 panel as observed 
under standard culture 
conditions. Figure reproduced 
from Berger et al109. 
 
 
 
 
 
 
In conclusion, these data provide experimental evidence on the accumulation of 
D-2-HG in mutIDH1/2 cancer cells and tissue due to production exceeding 
degradation. Explanation of in vivo D-2-HG levels is more complicated because of 
additional events like distribution across other body fluids (especially in AML patients) 
and many factors apparently impacting on the regulation of D2HDH. 
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7 Strategies for chiral analysis of 2-HG/-lactone 
For chiral analysis by hyphenated MS, two approaches could be considered given the 
equipment available at the Institute of Functional Genomics: one is using a chiral 
column, which can separate enantiomers because of different retention behavior. The 
other way is performing derivatization with specific reagents yielding diastereomers, 
which are no longer mirror images of each other and can be separated on standard 
columns due to different physicochemical properties. 
Cyclodextrin-based columns resolve chiral compounds based on the formation of 
inclusion complexes and are commonly used for enantioselective chromatographic 
separation. Kaunzinger et al. (1996) used a beta-cyclodextrin column for the 
enantioselective analysis of 2-hydroxyglutaric acids in urine113. Similarly, the method, 
which led to the discovery of the novel metabolite 2-HG-lactone in our lab, was a 
GC-EI-qMS method using a cyclodextrin column (Rt-γDEXsa). Sample preparation 
here included a methyl chloroformate (MCF)-derivatization. In general, alkyl 
chloroformates are frequently used reagents for the derivatization of metabolites as 
the reaction is fast, takes place at room temperature and can be performed in aqueous 
solution. MCF converts amino groups into volatile carbamates and carboxylic groups 
(-COOH) of organic acids into esters. For 2-HG two derivatization products were 
observed (Figure 13, see also Figure 2, chapter 3.1). 
Figure 13. Reaction scheme for 
MCF derivatization of 
2-hydroxyglutarate. 
Derivatization of 2-HG 
standards yielded two 
products: the ester of the 
2-HG-lactone (2-HG-lactone-
1E) as major product, but also 
the 3-fold derivative of 2-HG 
(2-HG-1MC-2E).  
(MC, methoxycarbonyl group; 
E, methyl ester group.) 
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The observation, that ratios of the two derivatives are stable for standard samples, but 
not for serum samples (of AML patients with IDH1/2 mutation) lead to the discovery of 
R-5-Oxo-2-tetrahydro-furancarboxylic acid (2-HG-lactone) as a novel metabolite (see 
also chapter 3.1, Figure 2). The formation of the one metabolite (2-HG-lactone) from 
the other metabolite (2-HG) during derivatization made this method redundant for 
simultaneous quantitative and enantioselective analysis of both metabolites. 
Nevertheless, a MS-method providing quantitative information on D- and L-2-HG and 
their corresponding lactones would be of great value to the analysis of biological 
samples. 
A very frequent derivatization in GC-analysis is silylation using reagents like MSTFA 
(N-methyl-N-(trimethylsilyl)-trifluoroacetamide). Through silylation, acidic hydrogen 
atoms in functional groups, such as -COOH, -OH, -NH and -SH, are replaced with a 
trimethylsilyl (TMS) group. As silyl derivatives are prone to hydrolysis in the presence 
of traces of water, anhydrous conditions are obligatory. Silylation is often combined 
with methoximation for a two-step derivatization strategy (methoximation followed by 
silylation) to extend coverage of derivatized metabolites. Oximation reagents, such as 
hydroxylamines or alkoxyamines, react with aldehyde and keto groups under basic 
conditions. This derivatization reaction is preventing ring formation of reducing sugars 
or keto-enol-tautomerism. Nevertheless, for analysis of 2-HG/-lactone on a 
cyclodextrin column, this strategy cannot be applied. As mentioned above silylation 
takes place at -OH groups, which are present on the cyclodextrin stationary phase, as 
well. Derivatization reagents are added in surplus and do not react completely but to a 
certain percentage remain in the sample. Thus, injecting samples after silylation would 
change column affinity and shorten its lifetime. Additionally, it was noticed that the 
derivatization regimen of methoximation followed by silylation causes ring opening of 
2-HG-lactone and can therefore not be used for the intended purpose. In chapter 8.1.1 
it is described, how derivatization including silylation still can be used for analysis of 
2-HG/-lactone.  
To circumvent the need for an enantioselective cyclodextrin column, it is possible to 
alternatively produce diastereomers by derivatization with respective reagents. 
Interestingly, Weibel et al. (2000)114 synthesized chiral silylation reagents for 
determination of absolute configuration by NMR spectroscopy. By using these 
reagents, separation of chiral analytes would be achievable on standard GC-columns. 
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However, synthesis of those chiral silylation reagents is quite laborious and they are 
not stable. Therefore, this approach is not feasible for rather small studies as needed 
here in the context of 2-HG-lactone in AML serum. Ding et al. (2018) described a 
GC-method for separation of lactic acid and 2-hydroxyglutaric acid enantiomers by 
chiral derivatization using L-menthol and acetyl chloride, combined with determination 
by MS115. Derivatization reagents here attack OH-groups, which is esterified in the 
lactone-form. Hence, this protocol is again not adaptable to 2-HG-lactone analysis. 
In addition, I tried enantioselective derivatization according to Gibson (see also 4.3.3). 
S-2-butanol was used for esterification of carboxyl-groups followed by acetylation with 
acetic anhydride. Applying this protocol to 2-HG and –lactone standard samples, the 
diastereomers of 2-HG were separated after analysis on a DB-Wax UI column (coupled 
to an EI-qMS; Figure 14; method details see chapter 5.5.5). For 2-HG-lactone the 
chromatogram basically looked the same, with the major peak corresponding to the 
2-HG-derivates. An additional, low abundant peak both, in 2-HG and –lactone 
standards, could be assigned to the 2-HG-lactone-derivative, but no separation of 
diastereomers was observed here (as described already by Duran et al. 19802). These 
observations are the result of a transesterification reaction of the intramolecular ester 
of 2-HG (=2-HG-lactone) and 2-HG-butyl-esters (which are the major and desired 
reaction products). This in the end means, that the Gibson-protocol cannot be applied 
to chiral analysis of 2-HG/-lactone. 
I also tried N-methyl-bis(trifluoroacetamide) (MBTFA) for derivatization. This reagent 
is used for acylation under mild, neutral conditions, instead of acetic anhydride, and 
would be combined with S-2-butanol for esterification. The milder conditions were 
expected to inhibit the formation of 2-HG-lactone from 2-HG (and vice versa). However, 
in practice, the method yielded poor derivatization efficiency and interconversion of the 
two metabolites. 
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Figure 14. Separation of D-2-HG (red) and L-2-HG (blue) after derivatization with S-2-butanol 
and acetic anhydride. (TIC of A= two separate standards, B= racemic standard). Derivatization 
gives rise to a derivative of 2-HG-lactone at RT~30.18 min, which is also of minor abundance 
for 2-HG-lactone standard samples (not shown). C) shows the mass spectrum of the 2-HG-
derivative. Structure of 2-HG (core in red) after derivatization with S-2-butanol and acetic 
anhydride. The blue line indicates the most intense specific fragment, m/z 173.1. 
Similar to these approaches by GC-MS, it is possible to derivatize chiral analytes to 
form diastereomers for separation on non-chiral LC-columns. There are different 
reagents available and some of those already were used in analysis of 2-HG. As 
mentioned in chapter 4.3.3, Struys et al. used DATAN to produce diastereomers of 
2-HG, which were analyzed on a C18 HPLC column80. Similarly, Cheng et al. (2015) 
formed diastereomers by TSPC (N-(p-toluenesulfonyl)-L-phenylalanyl chloride) 
labeling prior to LC-ESI-MS/MS analysis. This derivatization approach not only enables 
separation of D-/L-HG on a C18 HPLC column (VP-ODS, Shimadzu), but also offers 
enhanced sensitivity in comparison to DATAN derivatives116. Again, these 
Strategies for chiral analysis of 2-HG/-lactone  
51 
 
derivatization reagents attack the -OH of 2-HG, making them unsuitable for 
2-HG-lactone analysis. Moreover, there are also reagent for derivatization of carboxyl 
groups, such as (S)(+)-1-(2-pyrrolidinylmethyl)-pyrrolidine (S-PMP). Tsutsui et al. 
(2012) used this reagent for chiral analysis of lactic acid and 3-hydroxybutyric acid by 
LC-ESI-MS/MS117. However, for derivatization (which is an esterification of the 
carboxyl group) of 2-HG-lactone transesterification is expected to occur as described 
before. Thus, it would not be possible to quantitatively discriminate 2-HG and –lactone 
derivatives.  
Besides chiral GC-columns, there are also commercially available chiral LC-columns. 
But they are quite expensive. For instance, a Chirobiotic R column (glycopeptide 
antibiotic silica bonded column) was used for separation of 2-HG enantiomers in 
urine118. Here, LC was coupled to a Triple Quad MS run in MRM-mode. The method is 
reported to be sensitive and rapid, outperforming established chiral GC-methods with 
typically longer run times. Additionally, a chiral LC-column based on tert-
butylcarbamoyl-quinine and –quinidine (QN-AX, QD-AX) has been reported for the 
separation of D- and L-2-HG. Here, LC is coupled to a Charged Aerosol Detection 
(CAD), although LC-conditions are stated to be MS-compatible. Resolution for the two 
enantiomers is about 2.0 for a 20 min run119. None of these methods included 
2-HG-lactone. It might be worth trying whether a method separating D-/L-2-HG-lactone 
(and D-/L-2-HG in the same run) could be set up with such columns. Nevertheless, for 
this thesis such a column was not available and, therefore, it was not possible to 
perform these tests. 
Finally, an enantioselective (and quantitative) analysis of D-/L-2-HG and 
D-/L-2-HG-lactone could not be established, although various methods were tested. 
Mainly interconversion of 2-HG and -lactone hampered this comprehensive 
investigation. Generally, chiral analysis can also be accomplished by further 
techniques, which were beyond the scope of this thesis. By interfacing an ion mobility 
cell to a mass spectrometer, a further dimension of separation is gained. Dwevedi et 
al. (2006)120 introduced the concept of chiral IMS (ion mobility spectrometry), where 
ions are separated based on their stereospecific interaction with a chiral gas (e.g. 
S-2-butanol) which is mixed with the drift gas. Furthermore, for CE there are 
applications that are able to separate enantiomers121,122. In chiral‐CZE (capillary zone 
electrophoresis) and MEKC (micellar electrokinetic chromatography), chiral selectors 
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(CS) such as cyclodextrines are mixed with the buffer used as mobile phase. The CS 
and chiral analytes interact in an enantioselective fashion resulting in specific mobility. 
The coupling of this separations to MS, however, is somewhat problematical as chiral 
selectors are often non-volatile. In CEC (capillary electrochromatography), the chiral 
selectors are immobilized on the column, overcoming the problems at the interface to 
MS. Disadvantages with this mode are low robustness and low peak capacity. Finally, 
it can be said that further possibilities for chiral analysis of 2-HG&-lactone exist but 
would require extensive and systematic tests.  
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8 Investigating metabolism in mutIDH1/2 cells by tracer 
analysis 
To unravel the origin of the novel metabolite 2-HG-lactone, a tracer analysis was 
conducted. Metabolites, which are in high or even complete exchange and share the 
same carbon backbone, become apparent with matching MIDs. Beneath, labeling of 
metabolites with high exchange but different backbone can provide further information 
about metabolic changes in the respective system. Therefore, data on several 
metabolites generated by tracer analysis in the HCT116 panel (colon carcinoma) were 
collected and interpreted. 
8.1.1 GC-APCI-TOF-MS for tracer analysis 
Tracer analysis in this thesis was performed mainly using a GC-APCI-TOF-MS. The 
advantage in comparison to a GC-EI-qMS instrument is that APCI shows less or hardly 
any fragmentation. Because of extensive fragmentation EI-spectra are complex and 
Figure 15: Derivatization, methoximation followed by silylation, of 2-HG and 2-HG-lactone 
standards. For 2-HG lactone (red) several peaks are detected: RT~19.05 min is the 1TMS-
derivative, RT~23.05 min the 2-HG-3TMS formed by hydrolysis of the intramolecular ester of 
2-HG-lactone. The lower panel shows the spectrum of the latter peak, which is equal to that of 
the 2-HG standard (see also Figure 17). 
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unique fragment ions for all compounds of interest have to be identified. Contrarily, for 
APCI, detection of the intact [M+H]+-ion is possible, which facilitates interpretation and 
identification of labeling pattern. Additionally, the coupling to a TOF-analyzer provides 
high-resolution, resolving compounds and their isotopologues in full scan mode. In 
contrast, a Triple Quad instrument requires programming of transitions for all possible 
isotopologues, which can limit the number of compounds analyzed simultaneously.  
From the previous chapter it can be seen, that (GC-)MS-analysis of 2-HG and -lactone 
is challenging because of frequent interconversion of the two metabolites. 
Nevertheless, analysis of samples from this tracing experiments by GC-APCI-TOF-MS 
requires derivatization. For the enantioselective GC-application, as described before, 
silylation was not compatible. Contrarily, GC-separation of labeled metabolites is 
achieved on a standard non-polar 5 % diphenyl-dimethyl-polysiloxane column (Restek, 
Rxi-5ms). Standard procedure for methoximation followed by silylation in our lab (see 
also chapter 5.4.2) was found to result in identical spectra for 2-HG&-lactone because 
of transesterification of the intramolecular ester in 2-HG-lactone during derivatization 
(Figure 15).  
 
Figure 16. Silylation of 2-HG with MSTFA did not result in specific signals. The peak at 
~16.5 min is also detected in a derivatization blank. The signal at ~22.5 min belongs to the 
derivative of the internal standard undecanoic acid (C11). 
Silylation alone (incubation with MSTFA without addition of MeOx/pyridine) did not give 
intense signals, reaction efficiency was low (see Figure 16). But doing the reverse 
derivatization regime, starting with silylation followed by incubation with MeOx/pyridine 
worked out. Thus, obviously by addition of methoxylamine hydrochloride in pyridine 
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the reaction is facilitated. Pyridine is an acid scavenger and will drive the reaction 
forward by trapping the protons produced from the silylation reaction. Methoxylamine 
does not take over any function and could be left out. This derivatization produces a 
3-fold TMS derivative for 2-HG and for 2-HG-lactone the 1-fold TMS derivative (Figure 
17).  
 
Figure 17. The upper panel shows a chromatogram of 2-HG (green) and -lactone (red) 
standards after silylation with MSTFA and further incubation with pyridine. The peak at 
~23.05 min originates from the 2-HG-derivative. The corresponding spectrum is shown in the 
mid panel. The lower panel represents the spectrum of the 2-HG-lactone-derivative, which 
elutes at ~19.05 min. No side products for both 2-HG&-lactone(-derivatives) are detected. 
In addition to 2-HG and -lactone, other metabolites, e.g. TCA intermediates could be 
detected. Table 2 lists m/z-values and retention times used for data extraction with 
Compass QuantAnalysis software (Bruker, version 2.2). 
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Table 2. Overview of compounds included in the tracer analysis by GC-APCI-TOF-MS analysis 
including m/z-values of the [M+H]+-ion and retention times. The number of carbon atoms 
indicates mass shift of the fully labeled isotopologue. 
Compound m/z for [M+H]+ 
retention time 
[min] 
Number of 
carbon atoms 
2-HG 365.1 (3TMS) 23.3 5 
2-HG-lactone 203.1 (1TMS) 19.4 5 
α-KG 363.1 (3TMS) 24.2 5 
Succinate  263.1 (2TMS) 18.5 4 
Fumarate 261.1 (2TMS) 19.2 4 
Malate 351.2 (3TMS) 21.9 4 
Citrate 481.2 (4TMS) 26.8 6 
 
At the Institute of Functional Genomics there is an established method for 
LC-ESI-QqQ-MS analysis of organic acids. For analysis of labeling pattern, this 
analysis requires transitions for all possible isotopologues. For some analytes this even 
entails two transitions per isotopologue, when differentially labeled fragments are 
produced. On the other hand, this can provide structural information on which C-atom 
is labeled. Nevertheless, the new GC-APCI-TOF-MS method was expected to be more 
convenient including several analytes like organic acids, 2-HG &-lactone and further 
analytes amendable to silylation. A systematic evaluation of available analytes and 
sensitivity (especially in comparison to LC-ESI-QqQ-MS) was not feasible for time 
reasons. Yet, tracing data for TCA intermediates and 2-HG/-lactone from 
GC-APCI-TOF-MS and LC-ESI-QqQ-MS after correction for natural abundance were 
readily comparable (Figure 18). Bland-Altman plot for mean enrichment of TCA-
intermediates do not show a systematic error across all metabolites and variances are 
within the acceptable range (average mean difference ± 1.96 SD, represented by the 
doted lines). Succinate shows the highest differences between the two measurements 
(~4.8%) which is probably due to its low abundance and peaks close to the LOD, where 
variation is expected to be higher. α-KG analysis by LC is also known to be difficult 
because of bad peak shapes. Therefore, GC-data are expected to be more reliable. 
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Figure 18. Method comparison for tracer analysis by GC-APCI-TOF-MS and LC-ESI-QqQ-MS. 
The upper panel shows mean enrichment for glucose tracing in the HCT116 panel calculated 
from data aquired by both, GC-APCI-TOF-MS and LC-ESI-QqQ-MS. Bland-Altman plots for 
mean enrichment of all metabolites shown in the upper panel and in the lower panel for malate 
isotopologues and mean enrichment (continous lines represent mean difference, dotted line 
mean difference ± 1.96 SD; shown for metabolites/ isotopologues with most pronounced 
differences). 
Exemplary Bland-Altman plots for malate isotopologues (relative fractions) and mean 
enrichment reveal for M+0 and M+1 the most pronounced differences between the two 
approaches. M+0-fraction from LC-ESI-QqQ-MS is ~3% higher than from 
GC-APCI-TOF-MS, which results in an opposite difference for M+1 due to correction 
for natural abundance. The M+1 signal in the raw data can be attributed to either 
naturally labeled analytes or compounds labeled with one 13C originating from the 
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tracer. The correction algorithm calculates and subtracts the natural fraction based on 
the M+0 signal, thus reducing the M+1 fraction in this case for the LC-ESI-QqQ-MS 
data. Nevertheless, mean enrichment does not show much difference and is used for 
comparisons in the following chapters. Comparisons across isotopologues of one 
metabolite are not calculated. 
8.1.2 2-HG is the endogenous precursor of its lactone 
2-HG and its lactone are closely related metabolites with 2-HG-lactone being the 
intramolecular ester of 2-HG. Therefore, it can be assumed that 2-HG was the 
endogenous precursor of 2-HG-lactone. A tracing experiment was conducted to test 
this hypothesis. 13C5-glutamine is a frequently used tracer and is promising in this 
context. Glutamine is rapidly transformed via glutamate and α-KG into 2-HG (Figure 
20) theoretically resulting in acceptable enrichment to corroborate the expected 
connection between 2-HG and its lactone.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Labeling pattern of 2-HG (3-TMS-derivative, upper panel) and 2-HG-lactone 
(1-TMS-derivative, lower panel) from 13C5-glutamine tracing in HCT116 IDH1 R132H cells. 
Figure 19 shows an exemplary spectrum of 2-HG and -lactone from this tracing 
experiment. The m/z-values 203.1 and 365.2 correspond to the respective [M+H]+ and 
show the highest intensity. The m/z-values 208.1 and 370.2 represent the 
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corresponding M+5 isotopologues and derive from the production of 2-HG and -lactone 
from 13C5-glutamine. Other isotopologues are products of converging pathways, some 
of which can be found in Figure 20. In summary, the labeling patterns of the two 
metabolites reveal a similar isotopologue distribution, indicating that indeed 
2-HG-lactone is formed endogenously via intramolecular esterification of 2-HG. There 
are no hints that 2-HG-lactone is further metabolized other than by hydrolysis back to 
2-HG. 
 
Figure 20. Schemes 
depicting the expected 
isotopologues for TCA 
intermediates from 
13C6-glucose (upper 
panel) and 
13C5-glutamine tracing 
(lower panel), 
respectively. Each circle 
represents a carbon 
atom. Green circles 
originate directly from the 
tracer and are produced 
within the first round of 
the TCA cycle. Red 
circles represent tracer 
carbons incorporated 
during a second round of 
the TCA cycle. For 
glucose, the TCA is 
replenished from 
pyruvate/ acetyl-CoA, for 
glutamine from α-KG, 
which is indicated by the 
red arrows. 
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8.1.3 Tracer analysis in HCT116 cell panel 
By means of this tracer analysis, differences in cellular metabolism between cell lines 
of the HCT116 panel can be made visible. As mutIDH1/2 consumes an increased 
amount of α-KG, pathways for regeneration of α-KG might be upregulated. 
Furthermore, α-KG reduction by mutIDH1/2 is coupled to consumption of NADPH, 
which has to be regenerated to balance the cellular redox status. There are several 
enzymes which can produce NADPH, including WT-IDH1/2. Therefore, cells with 
mutation in IDH1/2 are affected twice with reduced production of NADPH while 
consumption is increased. Metabolic adaptation might differ between mutIDH1 and 
mutIDH2 cells due of the different localization of IDH1 and IDH2 to the cytosol and 
mitochondrion, respectively. For mitochondria, α-KG concentration is higher than in the 
cytosol123 and re-generation of the α-KG pool is expected to be higher due to the TCA 
cylce e.g. flux through IDH3. The fact that IDH2 is located in the mitochondrion is 
responsible for its independency on WT-IDH2 activity, in contrast to mutIDH1, which is 
dependent on WT-IDH1 for α-KG supply13. 
For this thesis, two different tracers were used, 13C5-glutamine (48 h of incubation) and 
13C6-glucose (24 h of incubation), which reveal a comparable mean isotopic 
enrichment in most of the TCA intermediates under these conditions. However, it has 
to be noted that maximal enrichment as a function of isotopic steady state was not 
tested systematically. Therefore, fractional contributions of glucose and glutamine 
cannot be compared directly and do not sum up to 100%. Mean enrichment might be 
increased by longer cultivation times. In addition, in glutamine tracing experiments, 
there was still FCS in the medium, contributing low amounts of unlabeled L-glutamine 
slightly diluting 13C5-glutamine. Thus, in these experiments enrichment form glutamine 
is always underestimated. 
Interestingly, the two cell lines with the highest 2-HG levels, HCT116 IDH1-R132H and 
-IDH2-R172K, show a higher mean isotopic enrichment in all TCA intermediates upon 
incubation with 13C5-glutamine compared to parental HCT116 and -IDH2-R140Q 
(Figure 21). Consequently, it can be concluded that the TCA cycle is replenished by 
glutaminolysis to compensate for the high α-KG demand. This is further supported by 
MIDs from glutamate, α-KG and 2-HG representing labeling from 13C5-glutamine 
(Figure 23), as well as higher mean enrichment in amino acids which can be formed 
from glutamine via the TCA cycle, e.g. Asp (Figure 22). Especially, M+5 of glutamate, 
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α-KG and 2-HG agree quite perfectly for mutIDH1/2 cells (statistics see Supplemental 
Table S 5). 
 
Figure 21. Mean isotopic enrichment in lactate, TCA intermediates and 2-HG/-lactone from 
13C6-glucose (upper panels) and 13C5-glutamine (lower panel). Labeling in lactate from 
glucose is not significantly different (ANOVA p= 0.891), for TCA intermediates differences are 
significant. For further statistics see Supplemental Table S 1 and Supplemental Table S 2. 
Notably, the parental HCT116 cell line, which does not have to compensate for 
increased α-KG consumption, shows the highest mean enrichment from 13C6-glucose 
in all TCA intermediates and other products which (can) contain carbon from glucose 
(e.g. Ala, Ser, Asp, Glu; Figure 21 and Figure 22). For HCT116 IDH1-R132H and -
IDH2-R172K, higher glutaminolysis was already detected, which ends up with lower 
mean enrichment in 13C6-glucose tracing. HCT116 IDH2-R140Q exhibit a lower 2-HG 
production than the other two mutant cell lines, but still are supposed to have a higher 
α-KG demand than the parental line. Nevertheless, this cell line shows lower 
enrichment for both, glucose and glutamine. This could be explained by further 
substrates used for replenishment of TCA cycle. For instance, it is known that other 
(unlabeled) substrates, like amino acids (α-KG anaplerosis via His, Pro, Arg124,125, 
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Asp/Asn-conversion into oxaloacetate126) and acetyl-CoA derived from fatty acid 
oxidation can refuel the TCA cycle for simultaneous energy production and supply of 
carbon backbones for biomass production. Contradictory is the labeling in amino acids 
like Asn, Ala and Ser from both tracers, which is not lower for HCT116 IDH2-R140Q, 
but for HCT116 IDH1-R132H.  
 
Figure 22. Mean isotopic enrichment in amino acids from 13C6-glucose (upper panels) and 
13C5-glutamine (lower panels). For further statistics, see Supplemental Table S 3 and 
Supplemental Table S 4. 
Lower mean enrichment from 13C6-glucose in TCA intermediates does not reveal a 
lower glycolytic flux in mutIDH1/2 cells. TCA anaplerosis from amino acids allows to 
forward glycolytic products to other pathways than TCA cycle, e.g. 
glucose-6-phosphate into pentose phosphate pathway (PPP) and acetyl-CoA into fatty 
acid synthesis. Especially PPP might be important in mutIDH1 cell, as it is the major 
source for cytosolic NADPH production127. Further measurements of the labeling 
pattern in the respective metabolites (e.g. ribose-5-phosphate, fatty acids) could clarify 
this issue. 
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Figure 23. MIDs from 13C5-glutamine tracing of glutamate, α-KG  and 2-HG. The highly similar 
labeling patterns indicate a high exchange between glutamate, α-KG and 2-HG. M+5 
isotopologues (as direct products of 13C5-glutamine) are only significantly different in HCT116 
IDH2-R140Q, ANOVA p= 0.0161(further statistics see Supplemental Table S 5). 
The TCA cycle can also be replenished via pyruvate carboxylase (PC) activity. 
Thereby, pyruvate from glycolysis is metabolized to oxaloacetate, which can run the 
TCA in the reverse direction into malate and fumarate yielding M+3 
isotopologues128,129. In the data from 13C6-glucose tracing in the HCT116 panel, M+3 
for fumarate and malate is higher than succinate M+3 indicating that pyruvate 
carboxylase is active (Figure 21, statistics see Supplemental Table S 9). This was 
already described for both, parental and HCT116-IDH1-R132H cells, and therefore 
might not be activated merely to compensate for 2-HG production. Contrarily, for 
astrocytes it was described that PC-flux is increased with mutIDH1/2 to maintain TCA 
activity130. 
For HCT116 IDH1-R132H cells, it has to be noted that labeling after incubation with 
13C6-glucose in alanine and serine differ from all other cell lines (also for 13C5-glutamine 
tracing, however, at a much lower level). These two metabolites are products of 
glycolysis and alanine is supposed to reflect mitochondrial pyruvate97,131. Contrarily, 
lactate reflects cytosolic pyruvate, but differences here in mean enrichment within the 
HCT116 cell panel are not significant. The reaction from pyruvate to alanine in 
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mitochondria is catalyzed by ALT2, which removes an amino-group form glutamate 
giving rise to α-KG. Especially in mutIDH2 cells, this represents another possibility to 
fuel α-KG into 2-HG production. However, in mutIDH1 cells with increased cytosolic 
α-KG consumption this obviously is regulated differently. Serine can be produced from 
glucose via D-3-phosphoglycerate dehydrogenase and degraded into pyruvate and 
similarly to alanine shows a lower M+3 and mean enrichment for HCT116 IDH1-R132H 
cells (statistics see Supplemental Table S 3 and Supplemental Table S 7). In contrast 
to other metabolites with contribution from glucose, this mutIDH1 cell line is not only 
lower than the parental line, but also lower than the two mutIDH2 cell lines. This is a 
trend, which can be observed in further metabolites, but is the most evident (~20% 
lower than parental) for serine and alanine.  
Figure 24. MIDs for alanine (mean enrichment ANOVA p=3.59*10-6) and serine (ANOVA 
p=3.86*10-5) from 13C6-glucose. Absolute concentrations of selected amino acids in cell 
extracts: alanine (ANOVA p= 4.10*10-3), serine (ANOVA, p= 3.86*10-5) and  aspartate 
(ANOVA p=5.15*10-5); For further statistics see Supplemental Table S 6 and intracellular 
amino acids see Supplemental Figure S2. 
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8.1.4 Mutant IDH1/2-related effects on cellular metabolism 
The described data on labeling pattern from culturing cells with13C5-glutamine and 
13C6-glucose can be combined with quantitative data to interpret changes in context of 
mutations in IDH1/2. For details about acquisition of quantitative data see chapter 6.5.2 
and 6.5.3.  
 
Figure 25. MIDs of aspartate, malate and citrate from 13C5-glutamine. Aspartate 
aminotransferase produces aspartate from malate, which causes matching labeling pattern. 
Reductive carboxylation generates citrate M+5  from 13C5-glutamine and hereinafter malate 
M+3, which is hardly observable, here. Thus, this pathway is not active. 
Glutaminolysis in mutIDH1/2 cells to enable 2-HG production was already described 
in several reports132-134. Accordingly, glutamate dehydrogenase (GLUD; for direct 
conversion of glutamate into α-KG) is upregulated in certain cancers including 
mutIDH1 glioma135. Besides, α-KG can be produced by aspartate aminotransferase 
(AAT; GOT1 cytosolic, GOT2 mitochondrial) using oxaloacetate and glutamate. 
By-product of this reaction is aspartate, which was found elevated in cell extracts of all 
mutIDH1/2 cell lines in comparison to the parental HCT116 (Figure 24). As 
oxaloacetate used by AAT is formed from malate in the TCA cycle and rapidly 
converted into aspartate, the latter has a similar labeling pattern to malate ( Figure 25).  
As mentioned before, the TCA can be replenished from other amino acids taken up 
from the environment, in this case cell culture medium. Remarkably, parental HCT116 
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cells tends to take up lower amounts of certain amino acids or even release more than 
the mutIDH1/2 cell lines (Figure 26, intracellular levels see Supplemental Figure S 2). 
The HCT116 IDH1-R132H clone shows the highest uptake and the lowest release, 
respectively. (High variances from calculating uptake/release make most differences 
not significant.) Increased uptake of amino acids for anaplerosis could be seen in mean 
enrichment of all downstream metabolites, as it dilutes the labeling from the main 
carbon sources, glucose and glutamine, in the respective tracing experiment. The most 
striking difference in mean enrichment and labeling pattern within the HCT116 panel 
was detected for alanine and serine. Thus, these two metabolites are apparently 
produced from sources other than glucose and glutamine in HCT116 IDH1-R132H 
cells. This might be a compartment specific effect, as this cell line is the only one with 
increased cytosolic α-KG demand and significantly decreased intracellular alanine 
levels (Figure 24). Serine is found at a lower concentration in HCT116 IDH2-R140Q 
cells. Generally, this amino acid is associated with purine synthesis and cytosolic redox 
balance. Still, the available data do not give a clear picture. For instance, it could not 
be unraveled, which alternative precursors were used for alanine and serine synthesis 
by using further tracers. 
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Figure 26. Uptake and release of selected amino acids (medium incubated with cells 
subtracted with blank medium, and normalized to cellular protein content). Significant 
differences were detected for glycine (ANOVA p=0.0087, Tukey´s HSD parental vs. 
IDH1-R132H padj=1.55*10
-4, parental vs. IDH2-R172K padj=2.97*10
-3, IDH1-R132H vs IDH2-
R140Q padj=2.17*10
-3) and serine (ANOVA p=0.0407, Tukey´s HSD parental vs. IDH2-R172K 
padj=3.8*10
-2). 
Regarding the adaptation to increased NADPH consumption by mutIDH1/2, the here 
presented data only provide minor information. Labeling from 13C6-glucose was found 
to be altered in all mutated HCT116 cell lines relative to the WT-cells. Using a different 
approach, Gelman et al. (2018) found increased glucose uptake and PPP-flux in 
HCT116 IDH1R132H cells compared to their wild-type counterpart136. This was 
deemed necessary to maintain lipogenesis, which requires NAPDH137. At the same 
time, uptake of palmitate from medium in mutIDH1 cells was observed and growth in 
delipidated medium was limited. Further, Molenaar et al. (2015) found decreased 
NADP+-dependent IDH activity in HCT116 IDH1-R132H cells in comparison to 
WT-IDH1/2 cells138. Similarly, NADPH production capacity was found to be reduced in 
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IDH1-R132H glioblastoma139. In contrast, in other tissues/cells, like in myeloid cells, 
PPP is responsible for most of the NADPH production capacity140. Besides, GLUD 
activity (see above glutaminolysis) for conversion of glutamate into α-KG uses NADP+ 
as cofactor, therefore producing NADPH while refueling the TCA. Additionally, 
mutIDH1 glioma cells can upregulate mitochondrial proline production from glutamine 
to maintain redox homeostasis141. However, labeling in proline in the here presented 
data does not support this finding for HCT116 cells.  
Maintaining fatty acid synthesis is critical to mutIDH1/2 cells. As mentioned above, 
lipogenic NADPH is increasingly produced by PPP and uptake of palmitate is essential 
for growth. Furthermore, it was shown that mutIDH1 cells exploit additional exogenous 
carbon sources such as acetate (if supplied with the medium) to produce acetyl-CoA 
for fatty acid synthesis136. Contrarily, cells with WT-IDH1/2 use (cytosolic) acetyl-CoA 
originating from mitochondrial citrate/TCA. Contribution of glutamine to fatty acid 
synthesis requires intact IDH1 activity and reductive carboxylation to derive citrate from 
glutamine. Reductive carboxylation is revealed by the formation of citrate M+5 upon 
feeding cells with 13C5-glutamine. In the cytosol, citrate (M+5) can be further converted 
to malate (M+3), which is also indicative of reductive glutamine metabolism142,143. 
Neither citrate M+5 nor malate M+3 were observed in the HCT116 panel ( Figure 25). 
Nevertheless, reductive glutaminolysis is rather active (in HCT116 cells) under hypoxic 
conditions133, when oxidative TCA flux needs to be down-regulated. Likewise, Badur 
et al. (2018) showed that mutIDH1 cells (HT1080), compared to WT-IDH1 cells, 
convert less glutamine to citrate/acetyl-CoA, while uptake of glutamine was 
increased137. Accordingly, glucose contribution to lipogenic acetyl-CoA in HT1080 cells 
is increased. If this is indeed the case for the HCT116 panel, this might be confirmed 
by measuring isotopic enrichment from 13C6-glucose and 13C5-glutamine, respectively, 
in fatty acids/palmitate. However, this was beyond the scope of the present study.  
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Moreover, reduced glycolysis and lactate production in mutIDH1 glioma was 
reported144. In accordance, LDHA (L-lactate dehydrogenase A catalyzing pyruvate 
conversion to lactate) and MCT1&4, responsible for lactate export, were found to be 
downregulated145,146. Similar results were presented by Mustafa et al. (2014), with 
overexpression of LDHA in glioma without IDH1 mutation and overexpression of LDHB 
(L-lactate dehydrogenase B) in mutIDH1 glioma to increasingly feed pyruvate into the 
TCA (see also Kurshed et al. 2017)135,144. For this thesis, neither lactate secretion nor 
glycolysis rate differed significantly between parental and mutIDH1/2 HCT116 cells 
(Figure 27). Glycolysis rate was calculated as percentage of one molecule glucose 
being converted into two molecules of lactate. Thus, increased PPP-flux towards 
ribose-5-phosphate for nucleotide synthesis (as an alternative way to use glucose not 
ending in lactate) would result in an altered glycolysis rate. Furthermore, enrichment 
Figure 27. Glycolysis and TCA in HCT116: Lactate secretion is lactate concentration in 
the supernatant minus the backgound signal detected in blank medium, normalized to 
cell protein content; glucose uptake is calculated likewise (lactate secretion ANOVA 
p=0.662, glucose uptake ANOVA p=0.557; n=2-3). Intracellular α-KG, pyruvate and 
lactate (normalized to parental HCT116; ANOVA: α-KG p=3.0*10-4, pyruvte p=4.83*10-6, 
lactate p=7.62*10-6; n=5-6). Glycolysis rate is the percentage of one molecule glucose 
being converted into two molecules of lactate (ANOVA p=0.479). For further statistics 
see Supplemental Table S 8. 
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in lactate is not significantly different within the HCT116 panel (ANOVA p=0.891; 
Figure 21). Consequently, the data presented here, do not indicate changes in the way 
glucose is consumed and the amount lactate is produced within the HCT116 cell panel. 
Further insights could be provided by measurements of PPP-metabolites and from 
additional experiments using 1,2-13C2-glucose as tracer. Additionally, discrepancies 
between our finding of unaltered glucose uptake (see also Grassian et al. 2014133) in 
parental HCT116 cells vs ~IDH1-R132H and increased glucose uptake in HCT116 
IDH1-R132H reported by Gelman et al. (2018)136 might be due to different cell culture 
conditions (glucose concentration in medium, incubation time). Rewiring of cell 
metabolism, especially (entry into) TCA cycle can also be seen from intracellular levels 
of α-KG, pyruvate and lactate (Figure 27). Levels of other TCA intermediates do not 
change significantly (data not shown). 
The main compensation mechanism for increased α-KG consumption is glutaminolysis 
and it is primarily dependent on the amount of 2-HG production. Regarding the 
localisation of mutIDH1/2, differences found were of minor impact. The most striking 
difference between HCT116 IDH1-R132H cells and HCT116 mutIDH2 cells is found in 
the labeling pattern of some amino acids, especially alanine and serine. It is assumed 
that depletion of IDH1 or IDH2, respectively, can be compensated by flux through the 
other isoform(s) and metabolite shuttles across the mitochondrial membrane. Likewise, 
Khurshed et al. (2017) concluded, based on gene expression data, that mitochondrial 
isocitrate production in mutIDH1 glioma is enhanced and shuttled to the cytosol for 
α-KG and 2-HG production144. Moreover, it was found that impaired mitochondrial 
IDH-flux (e.g. by IDH2 depletion) could be compensated by cytosolic WT-IDH1. For 
cells with a monoallelic IDH1 mutation, this increased WT-IDH1 flux even caused an 
increase of 2-HG production due to higher substrate availability for mutIDH113. The 
same was observed in HCT116 IDH1-R132H cells under hypoxic conditions, which 
increased oxidative IDH1-flux (citrate → α-KG + CO2)133. Interestingly, under these 
conditions, cells without IDH1 mutation increase reductive IDH1 flux to produce citrate 
for fatty acid synthesis. An IDH1 mutation results in the loss of this metabolic flexibility 
and, thus, in compromised growth under hypoxic conditions. As a result, there is also 
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a difference in nutrient supply (glucose vs. glutamine) for FA synthesis in mutIDH1 
cells under hypoxic conditions. 
In conclusion, the here presented data on metabolic adaptation in mutIDH1/2 cells 
using 13C-labeled compounds provide insight in the potential of this technique. The 
data are useful for understanding effects of increased 2-HG production by mutIDH1/2 
on cellular metabolism. However, to draw a complete picture, measurements need to 
be extended to further metabolites, like PPP and fatty acids. Additionally, based on 
these results, incubation times with tracers can be optimized. A paper summarizing all 
these efforts is planned for publication. 
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9 Origin and fate of 2-hydroxyglutarate-lactone 
This chapter summarizes the efforts made to study the novel metabolite 2-HG-lactone. 
The detection and confirmation of 2-HG-lactone was accomplished by applying 
different bioanalytical methods to serum samples obtained from AML-patients with 
mutated IDH1/2. Cell culture experiments using cells with mutIDH and WT-IDH 
provided evidence on the formation of 2-HG-lactone from 2-HG. 
 
9.1 2-HG and -lactone in various biological specimens 
Initially, the LC-MS/MS method described in chapter 5.5.1 was applied to a set of AML-
serum samples to investigate the respective serum levels of both, 2-HG and its 
metabolite 2-HG-lactone. This investigation led to the following insights (see also 
Figure 28A&B): 
- 2-HG is only present at elevated concentrations in patients with IDH1/2 mutation 
and decreases upon treatment, which is in agreement with the literature147-149. 
- 2-HG-lactone is only detected in samples with increased 2-HG concentrations, 
the ratio, however, varies. 
- The amount of 2-HG-lactone is not dependent on the type of IDH1/2 mutation, 
nor on the 2-HG level. 
In tissue extracts of glioma patients with IDH1/2 mutation, 2-HG-lactone concentration 
was just above the LLOQ, while 2-HG was detected in the mmolar range (Figure 28C). 
Thus, the ratio of 2-HG/-lactone was not comparable to AML-sera. This led to the 
assumption, that lactonization is a specific (enzymatic) reaction, which is hardly 
observable in the brain. Direct lactonization of 2-HG in the blood by serum enzymes 
was excluded by incubation of (fresh) serum and blood specimens with 2-HG at 37°C. 
These experiments did not reveal formation of 2-HG-lactone. Similarly, incubation of 
2-HG and α-KG with microsomal fractions (human microsomes & S9-fractions; life 
technologies; Carlsbad, USA) and recombinant IDH1/2 enzyme (Biomol, Hamburg & 
Amsbio, Abingdon, UK) did not result in 2-HG-lactone production (data not shown).  
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Figure 28. Analysis of 2-HG/-lactone in different biological specimens. A) Serum samples (bars 
represent meaurements of one patient each) of patients with IDH1/2 mutations. B) Follow-up 
of 2-HG/-lactone levels in serum (n=1) of a patient with an IDH2-R140Q mutation from 
diagnosis (first date) to ongoing treatment (causing a decrease in both metabolites) to relapse 
(last date). C) Glioma tissue with mutated and  wild type IDH1/2 (IDH1-mut: n=6, IDH2-mut: 
n=3, WT-IDH: n=5). 1000 pmol/mg tissue weight roughly translates to 1 mM assuming a tissue 
density of 1 g/mL. 2-HG-lactone constitutes about 3-4% of 2-HG, which is much lower than for 
AML-sera, where some samples show even higher levels of 2-HG-lactone than 2-HG. 
Furthermore, we asked, whether lactonization of 2-HG is specific to AML-patients with 
mutation in IDH1/2 and therefore elevated 2-HG concentrations or whether it can be 
found for instance in serum of 2-HG-aciduria patients, as well. Those patients also 
typically have augmented 2-HG serum concentrations, but we unfortunately did not get 
hold of such a sample for ethical reasons. 
In extracts of both, cell pellets and supernatants (e.g. from MCF7 and C7H2 cells), as 
expected, 2-HG was only found at baseline levels and 2-HG-lactone was below LLOQ 
or even LOD. Treatment of cells with D-2-HG led to increased intracellular D-2-HG 
concentrations, but it did not result in detectable production of 2-HG-lactone from 2-HG 
(Figure 29A&B). Interestingly, uptake of 2-HG&-lactone and intracellular hydrolysis of 
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2-HG-lactone varied across the cell lines tested. 2-HG is probably substrate to several 
transmembrane transporters: OAT1/4 (SLC22A6, SLC22A11)150 and the dicarboxylate 
transporter 3 (SLC13A3)151. 2-HG-lactone, as a monocarboxylate, is assumed to be 
transported by the widely expressed monocarboxylate transporters MCT1&4. 
Therefore, differences in the expression level of these transporters and intracellular 
esterases might explain alterations in intracellular 2-HG and -lactone levels across 
different cell lines. 
 
Figure 29. 2-HG/-lactone concentrations in cell extracts and supernatants. A) and B) show 
intracellular concentrations in two cell lines with WT-IDH1/2 (MCF7 and C7H2) after treatment 
with D-2-HG/-lactone for 72 h, as indicated (n=3). 2-HG-lactone is only detected intracellularly, 
when used for treatment but not as product of cellular 2-HG lactonization. Without treatment 
hardly any of the two metabolites are detected. C) depicts endogenous metabolite levels in 
media, and D) in cell extracts of the HCT116 panel (n=2-6). Here 2-HG-lactone is also 
detected, especially in supernatants of mutIDH1/2 cell lines. 
Administration of different concentrations (1-10 mM in medium) of D- and L-2-HG to 
various cell types (including primary macrophages, Supplemental Figure S 3) did not 
lead to the detection of significant amounts of 2-HG-lactone. These experiments 
suffered from low uptake rates of 2-HG. Therefore, I started to work on cells with an 
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IDH1 or IDH2 mutation, which produce 2-HG endogenously, namely HT1080 (IDH1-
R132C) and the HCT116 panel (IDH1-R132H, IDH2-R172K, and IDH2-R140Q mutant 
lines and parental line with baseline 2-HG). Indeed, all cell lines with an IDH1/2 
mutation had elevated intra- and extracellular 2-HG concentrations. Remarkably, no 
2-HG lactone was found in HT1080 extracts (Figure 33), whereas mutIDH1/2 HCT116 
contained 2-HG-lactone, especially in the supernatant (Figure 29C&D). The absolute 
concentrations of 2-HG-lactone, as well as the 2-HG/-lactone ratio, were altered within 
those three cell lines. Subsequently, the HCT116 panel was used as a model system 
to investigate the production, metabolism and effects of 2-HG-lactone. 
It has to be mentioned, that 2-HG-lactone is not stable in aqueous solutions, due to 
spontaneous hydrolysis into 2-HG. Preliminary data showed that the concentration of 
2-HG-lactone would be decreased by ~8% by this effect (see Supplemental Figure S 
4).  
 
9.2 2-HG-lactone formation is independent of IDH1/2 mutation 
During my work on this thesis, 2-HG-lactone was exclusively detected in the presence 
of IDH1/2 mutation. However, it was assumed that mutIDH1/2 was not directly involved 
in 2-HG-lactonization but necessary to provide sufficient 2-HG concentrations to detect 
2-HG-lactone formation. This question was addressed by administering 100 µM 
(2R)-2-hydroxyglutaric acid octyl ester (octyl-D-2-HG, structure see Figure 30) to 
parental HCT116 cells (WT-IDH1/2). The octyl-D-2-HG can diffuse across the cell 
membrane with intracellular hydrolysis of the ester giving rise to free 2-HG. Therefore, 
this treatment results in elevated intracellular D-2-HG concentrations even in 
WT-IDH1/2 cells. LC-MS/MS analysis confirmed elevated 2-HG levels both, in cell 
extracts and supernatant, as shown in Figure 30 A+B. Additionally, 2-HG-lactone was 
detected in samples from octyl-D-2-HG treated cells. In particular, extracellular 
concentrations of 2-HG-lactone were abundant, which agreed with endogenous 
2-HG/-lactone levels measured in mutIDH1/2 HCT116 cell lines (Figure 29). 
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Figure 30. 2-HG/-lactone concentrations in A) supernatant and B) cell extracts of octyl-D-2-HG 
(100 µM) treated parental HCT116 cells in comparison to untreated cells (n=2-3). Control 
medium, incubated without cells, reveals hydrolysis of octyl-D-2-HG even in absence of cells. 
However, elevated (intracellular) 2-HG levels alone do not entail detection of 
2-HG-lactone. In extracts of HT1080 cells for instance, there is endogenous 2-HG 
production from an IDH1-R132C mutation but 2-HG-lactone is not detectable. 
Therefore, it is assumed, that another factor, like an enzyme, is involved into 2-HG 
lactonization. 
Treatment of cells with octyl-D-2-HG was repeated with several other cell lines to test 
those cells for their capability to lactonize 2-HG (Figure 31). All tested cell lines were 
able to produce 2-HG-lactone upon octyl-D-2-HG treatment. Correlation of intra- or 
extracellular 2-HG and –lactone levels was not observed, but the concentrations of 
both metabolites and their ratio covered a wide range. Further work is needed to 
unravel what regulates the total amounts and the ratio of 2-HG and -lactone. 
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Figure 31. Extracellular (upper panel) and intracellular (lower panel) 2-HG/-lactone 
concentrations of selected cell lines of different origin treated with 100 µM Octyl-2-HG for 24 h 
(n=3). All cell lines have WT-IDH1/2, except HT1080 (IDH1-R132C; intracellular 2-HG is 
144.5 pmol/ µg protein). (Cell lines are of following origin: C7H2 - acute lymphoblastic T cell 
line, U397 and THP1 - monocytic leukemia , SW480 and LS174T - colorectal adenocarcinoma, 
MelIm - melanoma, J82 - bladder cancer, MCF7 - breast cancer, HT1080 - fibrosarcoma) 
 
9.3 Impact of pH on 2-HG-lactone formation 
Lactones are intramolecular esters and, therefore, the formation is favored under acidic 
conditions. We take advantage of this fact in the synthesis of our stable isotope labeled 
standard ([2,3,3]-D3-2-HG-lactone from [2,3,3]-D3-2-HG) required for quantitative 
LC-MS/MS analysis. Interestingly, there is a report about urine from a 2-HG-aciduria 
patient, where not only 2-HG but also the 2-HG-lactone was detected91. However, the 
authors also explain this finding with the low pH of the sample, which is as low as 
pH 2.5 (due to the addition of HCl before the measurement). 
To find out, what pH is low enough for lactonization of 2-HG, 1 mM D-2-HG was 
incubated in buffers of different pH values for 29 h at 37 °C. As shown in Figure 32, 
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the percentage of lactone formation increases with decreasing pH. At pH 5 
2-HG-lactone amounts to ~3% of 2-HG concentration.  
Figure 32: Spontaneous, non-enzymatic 
2-HG lactonization under acidified 
conditions. 1 mM D-2-HG was incubated in 
HEPES-buffer (20 mM) acidified with HCl 
to different pH values (at 37°C, 29 h, n=2 
per data point) and formed 2-HG-lactone 
was quantified. 
Physiological pH, in cell compartments like cytosol and mitochondria or in blood is 
supposed to be too high as it is tightly regulated in a neutral range. Extracellular 
acidification is a hallmark of cancer and was also verified for bone marrow in AML 
rats152. In the latter study, the pH dropped from 6.9 in the bone marrow of healthy rats 
to 6.5 in leukemic rats. Incubation time of 29 h (like in the experiment shown in Figure 
32) is rather short in comparison to an in vivo-situation like in an AML-patient. Besides, 
there is spontaneous hydrolysis of 2-HG-lactone released to the (strongly buffered) 
blood in AML-patients. Moreover, we know that 2-HG production by mutIDH1/2 is high; 
therefore, it seems unlikely that lactonization takes place already in the bone marrow 
of AML patients even in the case of pH being lowered by highly proliferating cancer 
cells. While peripheral myeloid cancer cells still can form 2-HG in the blood circulation, 
2-HG-lactone formation should be limited to the bone marrow because of the lower pH 
there. Such a situation will probably not lead to serum samples which present with 
higher 2-HG-lactone than 2-HG levels. 
To collect some evidence on lactonization as a function of environmental pH, cell 
culture experiments were preformed imitating alteration in extracellular pH. Namely, 
HT1080 cells (IDH1-R132C) were cultivated in acidified medium. (Cells were only 
cultivated for 6 h under these conditions to avoid a high number of dead cell in these 
samples due to the low pH). Although those cells produce 2-HG endogenously, 
lactonization cannot be observed under this experimental pH condition (Figure 33). 
Contrarily, for mutIDH1/2 HCT116 cells, which already produce 2-HG-lactone under 
standard culture conditions, cultivation in acidified medium causes a higher percentage 
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of 2-HG-lactone. Maybe this external pH drop stabilized the 2-HG-lactone produced in 
mutIDH1/2 HCT116 cells, but was not sufficient to induce lactonization in HT1080. 
 
Figure 33. 2-HG/-lactone levels in cell culture supernatants (A&C) and cell pellets (B&D), 
respectively, for HT1080 and HCT116 IDH2-R140Q cells. Each cell line was cultured for 6 h 
under standard and acidified conditions (pH of medium at time of addition was ~6.5). (n=2-3, 
percentages represent amounts of 2-HG-lactone relative to the sum of 2-HG/+lactone). 
2-HG-lactone is significantly different in HCT116 IDH2-R140Q (t-test: p=0.011). 
 
9.4 Investigations on lysosomes in context of 2-HG-lactone 
formation 
In cells the only compartment with low pH are lysosomes - intracellular vesicles 
responsible for degradation of waste products. Hydrolytic enzymes accomplish the 
breakdown of macromolecules targeted and internalized into lysosomes (via the 
endocytic pathway). To keep these enzymes active, the lysosomal lumen needs to 
maintain acidic pH, which is assured by the vacuolar-type H+-ATPase153. The average 
luminal pH in lysosomes is pH 4.5-5. This pH seems to be appropriate to produce 
detectable amounts of 2-HG-lactone. Formation of 2-HG-lactone in lysosomes would 
require fast and efficient export by a high affinity transporter, as intracellular 
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2-HG-lactone levels were found at a low level with 2-HG-lactone accumulation in cell 
culture supernatant and AML-serum. 
Moreover, it seems feasible that 2-HG is imported into lysosomes, which is a 
prerequisite for 2-HG-lactonization in lysosomes. For α-KG and other 
mono-/dicarboxylates transport across the lysosomal membrane by the human sialic 
acid transporter SLC17A5 was reported154,155. This anion transporter is rather 
unspecific and 2-HG and α-KG are very similar in their structure. Thus, it is assumed 
that 2-HG is a substrate of SLC17A5, as well.  
The number of lysosomes within a cell can vary dependent on environmental 
conditions like nutrient availability and alternating biomass turnover with concomitant 
changing degradation requirements156,157. To elaborate whether lysosomes are the 
crucial factor for lactonization of 2-HG, a staining of these compartments was 
performed. The area of stained spots per image was used as measure for lysosomal 
number. LysoTracker Deep Red is a commercially available dye for fluorescence 
microscopy, which selectively accumulates in acidic compartments, namely lysosomes 
and to some extent late endosomes. The fluorophore of LysoTracker is a weak base 
Figure 34. Representative images of HT1080, parental HCT116 und -IDH2-R172K cells 
stained with Hoechst 33342  (blue; nuclei) and LysoTracker Deep Red (red; lysosomes). 
Quantitative data in the right panel: Lysosomal staining calculated as the ratio of LysoTracker 
staining normalized to staining of nuclei with Hoechst 33342 in three different cell lines.  
(n=10 images, ANOVA p=2.13*10-6, post hoc-test=Tukey´s HSD). 
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and hardly protonated at neutral pH and can therefore easily cross cell membranes. At 
acidic pH, like in lysosomes, the fluorophore becomes protonated and is then trapped 
in that organelle. Consequently, this live cell imaging approach is highly selective and 
sensitive. For normalization, cell nuclei were simultaneously stained with 
Hoechst 33342 solution. Consequently, the relative staining (lysosomes/nuclei) should 
be higher for cells with more lysosomes. When assuming, that 2-HG-lactonization 
takes place in lysosomes, HT1080 cells should present significantly less lysosomal 
staining. However, staining of HT1080 cells and HCT116 cells does not reveal the 
expected differences (Figure 34). Comparison of LysoTracker staining (normalized to 
nuclei staining) rather showed the opposite difference. Consequently, lysosomes seem 
not to be solely responsible for 2-HG-lactonization. 
 
9.5 Does 2-HG-lactone formation involve an enzyme? 
Another aspect of lactone formation is the varying ratio of 2-HG and its lactone found 
in cell culture supernatant (but also in AML serum; Figure 28). The ratio seems not to 
be constant for a given type of IDH1/2 mutation.  
To check for a potential correlation between the concentration of 2-HG and its lactone, 
parental HCT116 cells and HCT116 IDH2-R172K cells were treated with increasing 
octyl-D-2-HG concentrations. In agreement with previous data, 2-HG-lactone was not 
detected in significant amounts in cell extracts, but only in cell supernatants (Figure 
35B). The extracellular 2-HG concentrations increased in a linear fashion (Figure 35A). 
This is true for control media incubated without cells, as well, but 2-HG concentrations 
are at a lower level. Thus, octyl-D-2-HG is to some extent hydrolyzed in culture medium 
releasing free 2-HG. The difference between control medium and cell supernatant, 
however, is due to export of intracellularly hydrolyzed/formed 2-HG. The 2-HG-lactone 
in supernatant of octyl-D-2-HG treated cells reveals a higher concentration for 
increasing (octyl-D-)2-HG levels. For the highest concentrations applied, 2-HG-lactone 
seems to reach saturation. Likewise, intracellular 2-HG concentrations seem to run into 
saturation, which however is not reached yet from the octyl-D-2-HG concentrations 
applied in this experiment (Figure 35C). 
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Figure 35. A) Extracellular 2-HG concentrations for parental HCT116 and ~IDH2-R172K cells 
depend on the octyl-D-2-HG concentration used for treatment (24 h). The difference in 2-HG 
concentration in mutant cells is attributed to endogenous 2-HG production from mutIDH2. 
Control (Ctrl)-medium is incubated without cells and, therefore, shows spontanous hydrolysis  
of octyl-D-2-HG. B) Corresponding extracellular 2-HG-lactone concentrations in parental 
HCT116 and IDH2-R172K HCT116. (No 2-HG-lactone in control-medium). C) Intracellular 
2-HG concentration depends on the octyl-D-2-HG concentration used for treatment of parental 
HCT116 from two independent experiments. Intracellular 2-HG-lactone is below the LLOQ.  
Finally, HT1080 cells were also treated with (different concentrations of) octyl-2-HG 
and now found to produce 2-HG-lactone (Figure 36). This is the more interesting, as 
intracellular 2-HG levels in treated HT1080 cells do not increase in comparison to 
untreated cells or with higher octyl-D-2-HG treatment as seen before for HCT116 cells. 
HT1080 cells show the highest (endogenous) intracellular 2-HG levels of all mutated 
cell lines measured (see also Figure 31). However, treatment with octyl-2-HG induces 
2-HG lactonization. Maybe there is an intracellular level for 2-HG, which when 
exceeded initiates lactonization to facilitate 2-HG removal. This critical level would then 
be higher in HT1080 than e.g. HCT116 and for HT1080 cells it would reflect almost the 
endogenous 2-HG level. Here, more experiments are needed. 
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Figure 36. A) Extracellular 2-HG concentrations for HT1080 cells depend on the octyl-D-2-HG 
concentration used for treatment (24 h). Control (Ctrl)-medium is incubated without cells and, 
therefore, shows spontanous hydrolysis  of octyl-D-2-HG. B) Corresponding extracellular 
2-HG-lactone concentrations in HT1080 cells from two independent experiments C) 
Intracellular 2-HG concentrations in octyl-D-2-HG treated HT1080 hardly correlate with octyl-
D-2-HG amounts used for treatment. The fluctuation as well as differences between the two 
experiments are due to differences in protein amount in the cell pellets. 
The increase in 2-HG-lactone concentration seen upon increasing concentrations of 
octyl-2-HG applied resembles a Michaelis-Menten-kinetic. This suggests, that an 
enzyme is involved in 2-HG-lactone formation (and/or export). Two mechanisms can 
be imagined explaining these findings. Either lactonization takes place intracellularly, 
with a high affinity transporter clearing the cells from 2-HG-lactone. Alternatively, 
2-HG-lactone is formed during export (by a transporter) to enhance 2-HG export. Both 
assumptions meet our findings of a more effective transport of the monocarboxylate 
2-HG-lactone than the dicarboxylate 2-HG (see below).  
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In macrophages incubated separately with D- and L-2-HG-lactone, respectively, it was 
observed that lactone hydrolysis was enantiospecific. As shown in Figure 37A&B 
uptake of 2-HG-lactone was comparable for the D- and L-form with a concentration 
dependent, linear increase in intracellular levels. Intracellular 2-HG concentrations 
reflect hydrolysis of 2-HG-lactone into the open ring form. Here, hydrolysis of D-2-HG-
lactone occurs more readily than that of L-2-HG-lactone (about 50-fold, Figure 
37C&D)). While for L-2-HG-lactone treatment, intracellular 2-HG levels again increase 
in a linear fashion, for D-2-HG-lactone intracellular 2-HG seems to run into saturation 
(comparable to the findings in octyl-D-2-HG treated cells, Figure 35).  
It has to be noted that generally donor dependent variances are given. For hydrolysis 
of D-2-HG-lactone there are two donors which show a considerably lower hydrolysis 
rate than the other donors, but which is still higher than for L-2-HG-lactone. This 
phenomenon needs to be followed up. Meanwhile, it can be concluded that 
2-HG-lactone hydrolysis is facilitated by an enzyme, because spontaneous hydrolysis 
Figure 37. Treatment of macrophages with D- and L-2-HG-lactone reveal enantiospecific 
effects. The upper panels give the intracellular 2-HG-lactone concentrations after treatment of 
cells with increasing amounts of A) D-2-HG-lactone and B) L-2-HG-lactone for 24 h. C) and D) 
give the respective intracellular 2-HG concentrations. For treatment enantiomerically pure 
solutions were prepared, LC-MS/MS measurements were not enantioselective but represent 
total 2-HG. Cells from Donor 1 were not treated with L-2-HG-lactone. 
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cannot occur in an enantioselective manner. However, it cannot be said whether this 
enzyme is also catalyzing the lactonization of (D-)2-HG. 
 
9.6 2-HG-lactone formation in cell homogenates 
To learn more about enzyme kinetics of 2-HG lactonization from the HCT116 panel, 
cells were lysed to perform enzyme assays. Cell homogenates were spiked with 2-HG 
as substrate and incubated at 37°C (similarly to D2HDH assay). Analysis of assay 
aliquots by LC-MS/MS do not reveal in vitro 2-HG-lactonization. Accordingly, no 
(active) enzyme catalyzing 2-HG-lactone formation is contained in cell homogenates. 
Inactivity could be explained by assay conditions, which do not recreate in vivo 
conditions. Altering assay conditions, like adding different salts/ ions (up to 25 mM 
potassium, 1 mM calcium, 2 mM zinc) and reducing agents (e.g. DTT), did not result 
in 2-HG-lactone formation. Interestingly, there are no human enzymes known that 
catalyze lactone formation. For other species there are, for instance the 
gluconolactonase (SMP30, regucalcin) involved into the vitamin C synthesis in mice158. 
Some lactonases can catalyze the reaction in both directions (lactone formation and 
hydrolysis) dependent on environmental conditions like pH. A lactonase (of unknown 
amino acids sequence) found in the bacterium Burkholderia sp. R-711, was described 
to hydrolyze D-2-HG-lactone, but lactone formation was not detected159. Nevertheless, 
is was considered that an esterase might be responsible for both, 2-HG lactonization 
and 2-HG-lactone hydrolysis. Variances in the 2-HG/-lactone ratio would then be a 
consequence of a shifted equilibrium, e.g. by changes in the pH.  
When adding 2-HG-lactone to cell homogenates (for incubation at 37°C for 5 h) to 
measure its hydrolysis, assay data do not reveal significant degradation. In conclusion, 
HCT116 cell homogenates do not contain an active esterase or any other enzyme, 
acting on D-2-HG and its lactone. Hence this approach does not contribute to explain 
our findings of 2-HG lactonization in AML-patients with IDH1/2 mutation.  
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Nevertheless, these results further support the hypothesis that 2-HG-lactone formation 
may be catalyzed by a transport protein embedded in the cell membrane. Such a 
protein (containing hydrophobic regions) is likely to be depleted during cell lysis and 
homogenate preparation in aqueous buffers. To increase solubility a detergent 
(DDM = n-dodecyl beta-D-maltoside) was added, which is assumed to retain enzyme 
activity, but again was not marked by success. Additionally, membrane gradients 
cannot be imitated in cell homogenates. Finally, there are several reasons which could 
hamper detection of 2-HG lactonization in cell homogenates. 
 
9.7 2-HG and its lactone are two distinct metabolites 
One could ask, why it is of importance to find the origin of 2-HG-lactone, if it is solely 
produced from and readily degraded to its precursor 2-HG. Investigation into potential 
biological effects of 2-HG/-lactone showed, for instance, a significant effect of D-2-HG 
and its lactone (in comparison to untreated controls) on the secretion of IL-6 from 
macrophages (Figure 39). In contrast, L-2-HG is not significantly different from 
controls. However, comparison to D-2-HG also does not give a significant difference 
(Tukey´s HSD padj=0.891). 
Figure 38. Assays for 2-HG-lactone degradation or 2-HG production, respectively. A) Lysate 
of HCT116 IDH1-R132H was spiked with 20 µM 2-HG-lactone and its concentrations was 
followed over 5 hours (n=2). Changes in concentration (normalized to concentrations at 0 
hours) was not significantly different from changes in 2-HG-lactone concentration incubated 
in blank buffer without protein (t-test p=0.139). Correspondingly, 2-HG concentrations (from 
incubation of 2 µM or 20 µM 2-HG-lactone) do not increase (B). 
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More interesting would be the differences in effects from the open vs the esterified 
2-HG. However, in the macrophage experiment, effects of D/-L-2-HG-lactone in 
comparison to D-/L-2-HG do not show a clear picture. IL6-secretion in L-2-HG-lactone-
treated cells was basically unaffected by treatment, which agrees with the before 
mentioned finding that L-2-HG-lactone was hardly hydrolyzed intracellularly (Figure 
37). Therefore, it appears that 2-HG is the compound evoking a (immune-) response, 
while the lactone does not. However, as the differences in lactone hydrolysis seem to 
be enantioselective and cell type specific, this issue needs further investigations. 
 
Figure 39. IL-6 secretion in primary macrophages 
from three different donors (normalized to untreated 
cells = Ctrl; all cells were stimulated with LPS). For 
10 mM D-2-HG and 1 mM D-2-HG-lactone 
treatment increase in IL-6 secretion is significant 
(ANOVA p=0.021; Dunnett test for pairwais 
comparison to Ctrl – vs D-2-HG p=0.0132, - vs 
D-2-HG-lactone p=0.0225, -vs L-2-HG p=0.0612). 
Data were generated in cooperation with the group 
of M. Kreutz (Department of Hematology and 
Oncology, University Hospital Regensburg).  
 
As mentioned before, 2-HG-lactone is assumed to be transported via MCT1&4. To 
investigate 2-HG-lactone transport by monocarboxylate transporters, a panel of 
LS174T cells was available comprising wild type and the knockout clones MCT1-/-, 
MCT4-/-, and MCT1-/- 4-/-, respectively160. Those four cell lines were again treated with 
100 µM octyl-D-2-HG, which resulted in increased intracellular 2-HG levels and 2-HG 
lactonization. As reported before for cells with WT-IDH1/2, 2-HG-lactone was hardly 
observable in pellet and medium extracts from LS174T cells grown under standard 
conditions (Figure 40A&C). For medium extracts of octyl-D-2-HG treated cells, 
2-HG-lactone was clearly detected for the full panel. Interestingly, when MCT1 was 
knocked out, extracellular 2-HG-lactone concentrations were lower indicating that 
MCT1 is the more efficient transporter (Figure 40B). At the same time there was an 
intracellular accumulation of 2-HG-lactone in those cells compared to WT-cells (Figure 
40E). In comparison to intracellular 2-HG, -lactone is still low abundant supporting the 
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hypothesis of an efficient clearing. On the contrary, MCT4-/- cells like WT-cells export 
2-HG readily, and -lactone does not accumulate intracellularly. For the MCT1-/- 4-/- cell 
line, -lactone is still found in the medium indicating that also other transporters are 
capable of exporting 2-HG-lactone. However, intracellular accumulation is significantly 
higher than in MCT1-/- cells (ANOVA p=1.27*10-9, Tukey´s HSD padj= 5.71*10-5), which 
might be due to intracellular acidification. MCTs are responsible for export of lactic 
acid, which was found elevated in pellet extracts of MCT4-/- and MCT1-/- 4-/- cells (Figure 
40F). If lactic acid is not removed from the cell, intracellular pH will drop which then 
pushes the equilibrium of 2-HG and –lactone towards lactone. These differences in 
intracellular pH might also explain the lower intracellular 2-HG amount in MCT4-/- cells. 
Low pH would not only stabilize the 2-HG-lactone, but also the octyl-D-2-HG. 
Therefore, it is supposed that measurement of intracellular octyl-D-2-HG would reveal 
higher levels of this compound for MCT4-/- and MCT1-/- 4-/- cells. But as 2-HG-lactone 
can leave MCT4-/- cells via MCT1, the concentrations of both metabolites are on a 
lower level. 
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Figure 40. LS174T panel treated with octyl-D-2-HG (100 µM, 24 h) reveals differences in 2-HG-
lactone transport. Extracellular levels (A&B) were corrected by differences in growth 
(according to a method suggested by Jain 2012161) as cells of this panel show different growth 
rates. Furthermore spontanous release of 2-HG from Octyl-2-HG was quantified in mediums 
incubated without cells and substracted from media samples. (n=1-6, especially for 2-HG-
lactone values were often below LLOQ). C,D&E) show intracelllar 2-HG/-lactone. Intracellular 
lactate (F) levels within the LS174T panel are significantly different (ANOVA untreated cells 
p=2.69*10-7, Octyl-D-2-HG treated cells p=3.09*10-4). Further statistics see Supplemental 
Table S 10 and Supplemental Table S 11 and Supplemental Table S 12. 
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10 Conclusions and Perspectives 
In this thesis, experiments were preformed to gain more insight into the oncometabolite 
D-2-hydroxyglutarate and its lactone. An enzymatic assay was developed to 
investigate the degradation of D-2-HG in the presence of IDH1/2 mutation. It was found 
that D-2-HG degradation by D2HDH is at vmax and is not increased in response to 
extracellular elevated D-2-HG levels. Contrarily, production of D-2-HG by mutated 
IDH1/2 is of higher capacity, which was hypothesized before in the literature. With this 
work this assumption was further supported by experimental evidence. For analysis of 
both metabolites, 2-HG and its lactone, an LC-MS/MS method was established and 
thoroughly validated. The origin of 2-HG-lactone, an intramolecular ester of 2-HG, is 
still unclear. It could be detected in cell lines when 2-HG concentrations are elevated 
either due to mutations in IDH1/2 or by treatment with cell permeable octyl-2-HG. 
However, high 2-HG-levels are not the only factor necessary for 2-HG-lactonization. 
With the evidence collected in this thesis, we hypothesize that a so far unidentified 
enzyme contributes to this intramolecular ester formation. Remarkably, lactone forming 
enzymes are not described for humans, rather lactonases catalyzing the reverse 
reaction of lactone hydrolysis.  
2-HG-lactone was found to exceed 2-HG concentrations in several AML-sera, while in 
glioma tissue it was detected only at 3-4% of 2-HG. Consequently, either the unknown 
enzyme is present at different levels and/or altered activity (dependent on 
environmental factors) or the level to which 2-HG needs to accumulate to start 
lactonization is cell type specific. Furthermore, 2-HG-lactone is mainly found in 
extracellular fluids like serum and cell culture supernatant. One might speculate that 
the lactone is formed to be exported acting in a kind of paracrine fashion. We 
investigated the effects of D-2-HG-lactone on immune cells, namely macrophages 
(regarding cytokine secretion). Further investigations need to focus on whether or to 
what degree those biological effects are distinct from D-2-HG. Besides, effects on other 
functional levels e.g. inhibitions of β-glucosidase would be of interest. Another question 
is, what effect 2-HG-lactone has for instance on progression and prognosis of AML. In 
general, identification of the mechanism behind 2-HG-lactonization and its 
manipulation would help to distinguish 2-HG and 2-HG-lactone mediated effects in 
cells of identical biological background. Also, a knock-out of the 2-HG-lactone 
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hydrolyzing esterase would aid in separating out effects of both, 2-HG and -lactone. 
Besides, it is of interest whether the 2-HG-lactone can be detected in patients with 
2-HG-aciduria, who also have increased serum 2-HG concentrations. 
Performing all these analyses was challenged by the fact that 2-HG and -lactone can 
be interconverted spontaneously. This fact made several established methods 
redundant and needed the development of new analytical methods and there are still 
areas for further improvement. 
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12  Supplement 
12.1  Supplemental Figures 
 
Supplemental Figure S 1. Chiral analysis of extracts of HT1080 and HCT116 IDH2-R140Q 
cells reveals that D-2-HG is the dominant enantiomer, while L-2-HG is present only at trace 
levels. Samples were derivatized as described in chapter 5.5.5. Purple lines represent 
standard samples, green line cell extracts. 
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Supplemental Figure S 2. Intracellular levels of selected amino acids in the HCT116 panel 
(normalized to parental HCT116; n=2-3). Stars indicate significant p-values from ANOVA. 
Further statistics see Supplemental Table S 6).l 
 
 
Supplemental Figure S 3. Primary macrophages of three different donors (bars represent 
n=1) were treated with 1 mM D- and L-2-HG, respectively. A) Extracellular 2-HG-lactone 
levels were hardly detectable and equal to <0.5% of 1 mM 2-HG. In untreated cells 
2-HG-lactone is below LLOQ. B) Intracellular 2-HG levels in treated cells tend to be higher 
compared to untreated, indicating uptake of D-/L-2-HG (paired t-test (treated vs untreated): 
pD-2-HG =0.1175, pL-2-HG =0.0825). 2-HG-lactone was not detected here. 
 
Supplement  
106 
 
 
Supplemental Figure S 4. 1000 µM D-2-HG-lactone was spiked into RPMI medium with (heat-
inactivated) and without FCS and incubated for 48 h. Shown here is the decrease in D-2-HG-
lactone concentration, which is due to spontaneous hydrolysis. On the opposite, 2-HG 
concentrations increases in the same fashion (not shown). Hydrolysis by an serum esterase 
from FCS can be excluded, as medium with and without FCS do not differ in their hydrolysis 
rate. This figure was prepared on preliminary data, kindly provided by K. Dettmer. 
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12.2  Supplemental Tables 
Supplemental Table S 1. Mean enrichment in intracellular TCA-intermediates and 
2-HG/-lactone from 13C6-glucose tracing in HCT116 cells. A one-way ANOVA was used to 
determine whether there are significant differences in mean enrichment between metabolites, 
while padj for pairwaise comparisons were computed using Tukey’s HSD (n=3). 
(1) Intracellular 2-HG-lactone concentrations are generally low abundant and mean isotopic 
enrichment from 13C6-glucose into 2-HG as the precursor is already low. Therefore, signals for 
 Parental IDH1-R132H IDH2-R172K IDH2-R140Q 
Lactate ANOVA p=2.15*10-3 
Parental   1.80*10-3   
IDH1-R132H   7.46*10-3 3.48*10-2 
IDH2-R172K     
IDH2-R140Q     
Citrate ANOVA p=6.26*10-6 
Parental   5.70*10-6 8.84*10-5 2.65*10-5 
IDH1-R132H   1.73*10-2  
IDH2-R172K     
IDH2-R140Q       
α-Ketoglutarate  ANOVA p=4.36*10-6   
Parental   3.0*10-6 4.45*10-5 7.42*10-5 
IDH1-R132H   1.25*10-2 5.37*10-3 
IDH2-R172K     
IDH2-R140Q     
2-Hydroxyglutarate ANOVA p=0.034  
Parental      
IDH1-R132H     
IDH2-R172K    3.15*10-2 
IDH2-R140Q     
2-HG-lactone ANOVA p=0.056 (1)   
Succinate ANOVA p=0.087 
Fumarate ANOVA p=5.68*10-7  
Parental   4.0*10-7 1.03*10-5 3.20*10-6 
IDH1-R132H   1.60*10-3 1.95*10-2 
IDH2-R172K     
IDH2-R140Q     
Malate ANOVA p=4.29*10-7 
Parental   3.0*10-7 1.35*10-5 2.10*10-6 
IDH1-R132H   5.56*10-4 2.69*10-2 
IDH2-R172K    4.53*10-2 
IDH2-R140Q     
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2-HG-lactone isotopologues are rather close to the noise level and differences are not 
significant. 
Supplemental Table S 2. Mean enrichment in intracellular TCA-intermediates and 2-HG/-
lactone from 13C5-glutamine tracing in HCT116 cells. A one-way ANOVA was used to 
determine whether there are significant differences in mean enrichment between metabolites, 
while padj for pairwaise comparisons were computed using Tukey’s HSD (n=3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
Citrate ANOVA p=9.66*10-6  
Parental    6.27*10-5  7.35*10-5  
IDH1-R132H     6.81*10-5 
IDH2-R172K    7.99*10-5 
IDH2-R140Q       
α-Ketoglutarate ANOVA p=6.33*10-5   
Parental   5.12*10-4 4.65*10-4  
IDH1-R132H    3.92*10-4 
IDH2-R172K    3.57*10-4 
IDH2-R140Q     
2-Hydroxyglutarate ANOVA p=1.07*10-4 
Parental   1.29*10-3 1.63*10-2  
IDH1-R132H    1.23*10-4 
IDH2-R172K    8.76*10-4 
IDH2-R140Q     
2-HG-lactone ANOVA p=4.08*10-6  
Parental   2.59*10-5 3.79*10-5  
IDH1-R132H    2.52*10-5 
IDH2-R172K    3.67*10-5 
IDH2-R140Q     
Succinate ANOVA p=1.04*10-4 
Parental   1.84*10-4 1.47*10-3  
IDH1-R132H    4.96*10-4 
IDH2-R172K    5.06*10-3 
IDH2-R140Q     
Fumarate ANOVA p=5.20*10-5 
Parental   1.97*10-4 6.77*10-4  
IDH1-R132H    2.13*10-4 
IDH2-R172K    7.42*10-4 
IDH2-R140Q     
Malate ANOVA p=2.84*10-5 
Parental   1.32*10-4 3.35*10-4  
IDH1-R132H    1.29*10-4 
IDH2-R172K    3.27*10-4 
IDH2-R140Q     
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Supplemental Table S 3. Mean isotopic enrichment in intracelluar amino acids from 
13C6-glucose tracing in HCT116 cells. A one-way ANOVA was used to determine whether there 
are significant differences in mean enrichment between metabolites, while padj for pairwaise 
comparisons were computed using Tukey’s HSD (n=3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
Alanine ANOVA p=3.59*10-6 
Parental   2.30*10-6 2.24*10-3 4.79*10-3 
IDH1-R132H   8.74*10-5 5.26*10-5 
IDH2-R172K     
IDH2-R140Q       
Serine ANOVA p=1.91*10-3   
Parental   2.15*10-3   
IDH1-R132H   4.46*10-3  
IDH2-R172K     
IDH2-R140Q     
Aspartate ANOVA p=5.4*10-6 
Parental   4.60*10-6 2.10*10-4 2.44*10-5 
IDH1-R132H   2.96*10-3  
IDH2-R172K     
IDH2-R140Q       
Glutamate ANOVA p=1.35*10-6   
Parental   1.00*10-6  1.05*10-5 
IDH1-R132H   2.54*10-3 1.15*10-2 
IDH2-R172K    2.36*10-5 
IDH2-R140Q     
 
 
 
 
 
 
 
Supplement  
110 
 
Supplemental Table S 4. Mean isotopic enrichment in intracellular amino acids from 
13C5-glutamine tracing in HCT116 cells. A one-way ANOVA was used to determine whether 
there are significant differences in mean enrichment between metabolites, while padj for 
pairwaise comparisons were computed using Tukey’s HSD (n=3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
Alanine ANOVA p=5.0*10-3 
Parental   8.24*10-3   
IDH1-R132H   7.37*10-3 2.23*10-2 
IDH2-R172K     
IDH2-R140Q       
Glutamate ANOVA p=3.12*10-5   
Parental   2.25*10-4 2.41*10-4  
IDH1-R132H    1.96*10-4 
IDH2-R172K    2.10*10-4 
IDH2-R140Q     
Aspartate ANOVA p=7.97*10-5 
Parental   7.15*10-4 5.50*10-4  
IDH1-R132H    5.18*10-4 
IDH2-R172K    4.02*10-4 
IDH2-R140Q       
Asparagine ANOVA p=1.47*10-7   
Parental   5.0*10-7   
IDH1-R132H   2.0*10-7 8.0*10-7 
IDH2-R172K     
IDH2-R140Q     
Proline ANOVA p=5.68*10-5   
Parental    3.78*10-4 8.03*10-4 
IDH1-R132H   2.06*10-4 4.17*10-4 
IDH2-R172K     
IDH2-R140Q     
 
Supplemental Table S 5. Significant differences in M+5 isotopologues from 13C5-glutamine 
tracing for glutamate, 2-HG and α-KG. Differences in fractional abundance between 
metabolites were tested with one-way ANOVA, significant padj for pairwaise comparisons were 
computed using Tukey´s HSD (n=3). 
 Parental IDH1-R132H IDH2-R172K IDH2-R140Q 
ANOVA 2.07*10-2 0.054 0.332 0.860 
Glu vs α-KG     
2-HG vs α-KG 2.26*10-2    
2-HG vs Glu     
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Supplemental Table S 6. Sigificant differences in intracellular amino acid concentrations: 
differences between cell lines were tested with ANOVA, significant padj for pairwaise 
comparisons are from Tukey´s HSD and Dunnett-test for aspartate for test vs. control=parental 
HCT116 (n=2-3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
Alanine ANOVA p=4.10*10-3 
Parental   3.38*10-3   
IDH1-R132H   2.10*10-2 2.35*10-2 
IDH2-R172K     
IDH2-R140Q       
Serine ANOVA p=3.86*10-5 
Parental     7.78*10-5 
IDH1-R132H    4.32*10-5 
IDH2-R172K    8.40*10-5 
IDH2-R140Q       
Aspartate ANOVA p=5.15*10-5 
Dunnett: 
Parental vs: 
 2*10-4 5.1*10-5 4.2*10-5 
Proline ANOVA p=9.26*10-5 
Parental   4.01*10-3 1.11*10-4 2.42*10-4 
IDH1-R132H   1.46*10-2 2.78*10-2 
IDH2-R172K     
IDH2-R140Q       
Histidine ANOVA p=5.59*10-4 
Parental   1.29*10-3  1.67*10-3 
IDH1-R132H   6.91*10-3  
IDH2-R172K    7.77*10-3 
IDH2-R140Q       
Glutamate ANOVA p=0.201 
Arginine ANOVA p=0.117 
Asparagine ANOVA p=0.210 
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Supplemental Table S 7. Significant differences in M+3 isotopologues from 13C6-glucose 
tracing for alanine and serine. Differences in fractional abundance between metabolites were 
tested with ANOVA,  significant padj for pairwaise comparisons are from Tukey´s HSD (n=3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
Alanine ANOVA p=3.80*10-6 
Parental   2.50*10-6 2.64*10-3 5.91*10-3 
IDH1-R132H   8.71*10-5 5.13*10-5 
IDH2-R172K     
IDH2-R140Q       
Serine ANOVA p=1.37*10-4 
Parental   1.18*10-4  1.80*10-2 
IDH1-R132H   5.55*10-4 6.95*10-3 
IDH2-R172K     
IDH2-R140Q       
 
Supplemental Table S 8. Significant differences in intracellular levels of α-KG, pyruvate and 
lactate in the HCT116 panel. A one-way ANOVA was used to determine whether there are 
significant differences in mean enrichment between metabolites, while padj for pairwaise 
comparisons were computed using Tukey’s HSD (n=3). 
 Parental   IDH1-R132H IDH2-R172K IDH2-R140Q 
α-Ketoglutarate ANOVA p=3.03*10-4 
Parental   1.04*10-3   
IDH1-R132H    6.67*10-4 
IDH2-R172K     
IDH2-R140Q       
Pyruvate ANOVA p=4.83*10-6 
Parental   2.01*10-4 1.22*10-3 3.10*10-6 
IDH1-R132H     
IDH2-R172K    3.02*10-2 
IDH2-R140Q       
Lactate ANOVA p=7.62*10-6 
Parental   1.60*10-5 9.25*10-5 1.18*10-5 
IDH1-R132H     
IDH2-R172K    9.09*10-3 
IDH2-R140Q       
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Supplemental Table S 9. Test for significant differences in mean isotopic enrichment of malate, 
fumarate and succinate from 13C6-glucose tracing as an indicator of PC-activity. A one-way 
ANOVA was used to determine whether there are significant differences in mean enrichment 
between metabolites, while padj for pairwaise comparisons were computed using Tukey’s HSD 
(n=3). 
 Parental IDH1-R132H IDH2-R172K IDH2-R140Q 
ANOVA  0.32*10-4 6.67*10-3 2.06*10-4 2.11*10-3 
Malate vs 
Fumarate  
0.320 0.202 0.449 0.391 
Fumarate vs 
Succinate 
7.76*10-4 4.91*10-2 5.94*10-4 8.07*10-3 
Malate vs 
Succinate 
2.64*10-4 5.62*10-3 2.52*10-4 2.14*10-3 
 
Supplemental Table S 10. Tests for significant differences in intracellular lacate levels in 
octyl-D-2-HG treated cells of the LS174T panel and untreated control cells. A one-way ANOVA 
was used to determine whether there are significant differences in mean enrichment between 
metabolites, while padj for pairwaise comparisons were computed using Tukey’s HSD (n=3). 
 WT MCT1-/- MCT4-/- MCT1-/-MCT4-/- 
untreated ANOVA p= 2.69*10-7   
WT   8.00*10-7 1.30*10-6 
MCT1-/-   4.70*10-6 9.30*10-6 
MCT4-/-     
MCT1-/-
MCT4-/- 
    
Octyl-D-2-HG ANOVA p= 3.09*10-4   
WT     
MCT1-/-   6.77*10-4 4.48*10-4 
MCT4-/-     
MCT1-/-
MCT4-/- 
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Supplemental Table S 11. Tests for significant differences in intracellular 2-HG & -lactone in 
octyl-D-2-HG treated cells of the LS174T panel and untreated control cells. Differences were 
tested with one-way ANOVA, significant padj for pairwaise comparisons are from Tukey´s HSD. 
 WT MCT1-/- MCT4-/- MCT1-/-MCT4-/- 
untreated ANOVA p= 6.66*10-6 / values below LLOQ  
WT  2.49*10-3 4.17*10-3) 5.32*10-4 
MCT1-/-   2.55*10-5 7.50*10-6 
MCT4-/-     
MCT1-/-
MCT4-/- 
    
Octyl-D-2-HG ANOVA p= 1.46*10-4 / p= 1.27*10-9  
WT   3.46*10-4  
MCT1-/- 3.11*10-8  1.74*10-4  
MCT4-/-  6.37*10-8  1.57*10-3 
MCT1-/-
MCT4-/- 
5.45*10-9 5.71*10-5 8.16*10-9  
 
Supplemental Table S 12. Tests for significant differences in extracellular 2-HG & -lactone in 
octyl-D-2-HG treated cells of the LS174T panel and untreated control cells. Differences were 
tested with one-way ANOVA, significant padj for pairwaise comparisons are from Tukey´s HSD. 
 WT MCT1-/- MCT4-/- MCT1-/-MCT4-/- 
untreated ANOVA p= 9.95*10-5/ p= 0.249   
WT  2.15*10-4 1.32*10-2  
MCT1-/- 1.00*10-7  2.34*10-2 1.60*10-4 
MCT4-/-  2.00*10-7  8.52*10-3 
MCT1-/-
MCT4-/- 
    
Octyl-D-2-HG ANOVA p= 0.023 / p= 1.29*10-8  
WT   3.46*10-4  
MCT1-/-   1.74*10-4  
MCT4-/- 2.69*10-2 3.93*10-2  1.57*10-3 
MCT1-/-
MCT4-/- 
3.88*10-8  1.00*10-7  
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14 Summary 
 
This thesis investigated the impact and metabolism of the known oncometabolite 
D-2-hydroxyglutarate and its recently recognized lactone R-5-oxo-2-tetrahydro-
furancarboxylic acid. Production and biological effects of 2-hydoxyglutarate are well 
described in the literature. However, accumulation of this metabolite as a result of 
insufficient degradation was studied for the first time in this thesis. Therefore, a cell-
based enzyme assay was developed to measure D-2-hydoxyglutarate degradation by 
D-2-hydroxyglutarate dehydrogenase. Quantification of 2-hydroxyglutarate was 
accomplished by LC-MS/MS. Applying this assay, it was found that 
D-2-hydroxyglutarate dehydrogenase activity differs across cell lines but is not 
upregulated in response to elevated 2-hydroxyglutarate levels.  
Moreover, in preliminary investigations on 2-hydroxyglutarate in serum of AML-patients 
with mutations in isocitrate dehydrogenase, 2-hydroxyglutarate-lactone was 
discovered. The HCT116 panel with IDH1/2 mutation served as a model to learn more 
about the novel metabolite as both metabolites – 2-HG and 2-HG-lactone - can be 
detected in extracts of these cells. Thereby, 2-hydroxyglutarate was verified as the 
precursor by performing 13C5-glutamine tracing experiments. However, 
2-hydroxyglutarate lactonization does not take place whenever the precursor is 
abundant, as for some biological specimens with elevated 2-hydroxyglutarate the 
lactone was not detectable. Further experiments provided hints that 
2-hydroxyglutarate-lactone is of enzymatic origin but did not lead to the identification 
of this enzyme.  
In doing all these experiments, interconversion of 2-hydroxyglutarate and its lactone 
needed to be controlled and required development of new protocols using different 
approaches of hyphenated mass spectrometry. For instance, set up of an 
enantioselective analysis of 2-hydroxyglutarate and its lactone was an objective of this 
thesis but was not achieved with the possibilities at the institute. Finally, this thesis 
provided insights into origin, fate and impact of 2-HG and 2-HG-lactone in the context 
of tumor metabolism. 
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15 Zusammenfassung 
 
Diese Arbeit untersuchte die Auswirkungen und den Stoffwechsel von Onko-
Metaboliten am Beispiel von D-2-Hydroxyglutarat und seinem Lacton, R-5-Oxo-2-
tetrahydrofurancarbonsäure mit Hilfe einiger bioanalytischer Methoden. Die 
Produktion und die biologischen Effekte von 2-Hydroxyglutarat sind in der Literatur gut 
beschrieben. Im Gegensatz dazu wurde in dieser Dissertation die Akkumulation dieses 
Metaboliten in Folgen seines ungenügenden Abbaus zum ersten Mal genauer 
untersucht. Um den Abbau von D-2-Hydroxyglutarat durch die D-2-Hydroxyglutarat-
Dehydrogenase zu messen, wurde ein Zell-basierter Assay entwickelt. Die 
Quantifizierung von 2-Hydroxyglutarat erfolgte mittels einer LC-MS/MS-Methode. Die 
Anwendung des Enzym-Assays auf verschiedene Zelllinien zeigte unterschiedliche 
Aktivitäten für die D-2-Hydroxyglutarat-Dehydrogenase, die durch erhöhte 
2-Hydroxyglutarat-Spiegel jedoch nicht wie erwartet hoch reguliert wurde.  
Außerdem wurde bei (dieser Arbeit vorangegangener) Untersuchungen zu 
2-Hydroxyglutarat in Serum von AML-Patienten mit Mutation der Isocitrat-
Dehydrogenase das 2-Hydroxyglutarat-Lacton, der intramolekulare Ester des 
2-Hydroxyglutarats, als endogener Metabolit identifiziert. Um mehr über den neuen 
Metaboliten zu erfahren, wurden einige Experimente durchgeführt. Dabei diente ein 
Set aus HCT116 Zelllinien, bestehend aus Zelllinien mit und ohne IDH1/2-Mutation als 
wichtiges Modell, da in Extrakten dieser Zellen sowohl 2-Hydoxyglutarat als auch das 
-Lacton nachgewiesen wurde. So zeigten Untersuchungen des Stoffwechsels in Zellen 
mit IDH1/2-Mutation durch Zugabe von 13C5-Glutamin, dass das 
2-Hydroxyglutarat-Lacton aus 2-Hydroxyglutarat gebildet wird. Weitere Daten dieses 
Versuchs zusammen mit Ergebnissen aus einem analogen Versuch, bei dem 
13C6-Glucose eingesetzt und dessen Verstoffwechselung nachverfolgt wurde, zeigten 
die Auswirkungen einer IDH1/2-Mutation auf den zellulären Stoffwechsel. So wurde 
z.B. klar, dass diese Zellen vorwiegend Glutamin nutzten, um den erhöhten Verbrauch 
von α-Ketoglutarat zur 2-Hydroxyglutarate-Synthese zu kompensieren. In Extrakten 
von einigen Seren oder Zellkultur-Proben mit erhöhtem 2-Hydroxyglutarat-Wert war 
das -Lacton nicht detektierbar. Daher scheint es, dass 2-Hydroxyglutarat in 
ausreichender Konzentration allein nicht ausreicht, um eine Laktonisierung 
beobachten zu können. In Zellkultur-Versuchen etwa wurde der 2-Hydroxyglutarat-
Spiegel durch Zugabe des Zellmembran-permeablen 2-Hydroxyglutarate-Octyl-Esters 
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unabhängig von einer IDH1/2-Mutation erhöht und immer die Laktonisierung 
beobachtet. Weitere Experimente lieferten Hinweise, dass das 2-Hydroxyglutarat-
Lacton enzymatischen Ursprungs ist, aber letztendlich konnte das verantwortliche 
Enzym nicht identifiziert werden.  
Es wurden daneben auch Versuche zu Untersuchung der biologischen Effekte von 
2-Hydroxyglutarat und -Lacton z.B. auf die Immunantwort von Makrophagen 
durchgeführt. Dabei wurde auch festgestellt, dass die Aufnahme-Raten von 
2-Hydroxyglutarat und -Lacton (vermutlich bedingt durch verschieden Transporter) 
sich unterscheiden. Ebenso ist die intrazelluläre Hydrolyse-Rate des Lactons Zelltyp-
spezifisch und erfolgt zumindest in Makrophagen enantioselektiv. Letztendlich war es 
schwer möglich, biologische Effekte eindeutig einem der beiden Metabolite, 
2-Hydroxyglutarat und -Lacton, zuzuordnen. 
Bei der Durchführung aller Versuche zu dieser Arbeit musste stets die mögliche, 
gegenseitige Umwandlung von 2-Hydroxyglutarat und -Lacton im Auge behalten 
werden. Daher wurde es auch notwendig, neue Methoden aus dem Bereich der 
gekoppelten Massenspektrometrie zu entwickeln. Beispielsweise wurde versucht eine 
enantioselektive Methode zur Quantifizierung von D-/L-2-Hydroxyglutarat und -Lacton 
zu etablieren. Hierzu wurden zwei verschiedene Ansätze getestet: zum einen die 
Verwendung enantioselektiver Chromatographie-Säulen, zum anderen eine 
Derivatisierung mit chiralen Reagenzien, wodurch Diasteromere entstehen. Jedoch 
war es mit den am Lehrstuhl verfügbaren Instrumenten und Mitteln nicht möglich eine 
valide, enantioselektive Methode für beide Analyten aufzusetzen. Die Ergebnisse 
dieser Arbeit basieren dementsprechend hauptsächlich auf Messungen mit einer 
(LC-MS/MS)-Methode, die Enantiomere nicht unterscheiden kann, bzw. auf Daten 
chiraler GC-MS-Analysen von 2-Hydroxyxglutarat. So konnten dennoch einige 
Erkenntnisse über den Ursprung, das Schicksal und den Einfluss von zwei Metaboliten 
im Kontext des Tumor-Stoffwechsels gewonnen werden. 
 
  
119 
 
 
Eidesstattliche Erklärung  
 
Ich erkläre hiermit, dass ich die vorliegende Arbeit selbst verfasst und keine anderen 
als die angegebenen Quellen und Hilfsmittel verwendet habe.  
 
 
-----------------------------------  -------------------------------------- 
Ort, Datum  Unterschrift 
